Negative	O
transcriptional	O
regulation	O
of	O
human	B-DNA
interleukin	I-DNA
2	I-DNA
(	I-DNA
IL-2	I-DNA
)	I-DNA
gene	I-DNA
by	O
glucocorticoids	O
through	O
interference	O
with	O
nuclear	B-protein
transcription	I-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

IL-2	B-DNA
gene	I-DNA
transcription	O
is	O
affected	O
by	O
several	O
nuclear	B-protein
proteins	I-protein
.	O

We	O
asked	O
whether	O
dexamethasone	O
(	O
Dex	O
)	O
and	O
cyclosporin	O
A	O
(	O
CsA	O
)	O
inhibit	O
IL-2	B-DNA
gene	I-DNA
transcription	O
by	O
interfering	O
with	O
the	O
activity	O
of	O
nuclear	B-protein
proteins	I-protein
that	O
bind	O
to	O
the	O
IL-2	O
promoter	O
.	O

Nuclear	O
extracts	O
from	O
primary	B-cell_type
human	I-cell_type
T	I-cell_type
lymphocytes	I-cell_type
were	O
analyzed	O
by	O
electrophoretic	O
DNA	O
mobility	O
shift	O
assays	O
.	O

Both	O
Dex	O
and	O
CsA	O
inhibited	O
the	O
binding	O
of	O
transcription	O
factors	O
AP-1	B-protein
and	O
NF-AT	B-protein
,	O
but	O
not	O
of	O
NF-kB	B-protein
and	O
OCT-1/OAF	B-protein
,	O
to	O
their	O
corresponding	O
sites	O
on	O
the	O
IL-2	B-DNA
gene	I-DNA
promoter	I-DNA
.	O

To	O
correlate	O
changes	O
in	O
nuclear	O
factor	O
binding	O
in	O
vitro	O
with	O
transcriptional	O
activity	O
in	O
vivo	O
and	O
define	O
the	O
structural	O
requirements	O
for	O
IL-2	B-DNA
promoter	I-DNA
repression	O
,	O
we	O
used	O
transient	O
DNA	O
transfections	O
.	O

Jurkat	B-cell_line
cells	I-cell_line
were	O
transfected	O
with	O
plasmids	B-DNA
containing	O
either	O
the	O
intact	O
IL-2	B-DNA
promoter	I-DNA
or	O
its	O
AP-1	B-DNA
,	I-DNA
NF-AT	I-DNA
,	I-DNA
and	I-DNA
NF-kB	I-DNA
motifs	I-DNA
.	O

Dex	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
AP-1	B-DNA
,	O
but	O
not	O
the	O
NF-AT	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

In	O
contrast	O
,	O
CsA	O
inhibited	O
the	O
IL-2	B-DNA
promoter	I-DNA
and	O
the	O
NF-AT	B-DNA
,	O
but	O
not	O
the	O
AP-1	B-DNA
and	O
NF-kB	B-DNA
plasmids	I-DNA
.	O

These	O
results	O
suggest	O
that	O
in	O
human	B-cell_type
T	I-cell_type
lymphocytes	I-cell_type
both	O
Dex	O
and	O
CsA	O
inhibited	O
IL-2	B-DNA
gene	I-DNA
transcription	O
through	O
interference	O
with	O
transcription	B-protein
factors	I-protein
AP-1	B-protein
and	O
NF-AT	B-protein
.	O

We	O
propose	O
that	O
,	O
while	O
maximum	O
inhibition	O
may	O
involve	O
interaction	O
with	O
both	O
transcription	B-protein
factors	I-protein
,	O
AP-1	B-protein
is	O
the	O
primary	O
target	O
of	O
Dex	O
.	O

Negative	NULL
Transcriptional	NULL
Regulation	NULL
of	NULL
Human	NULL
Interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
Gene	NULL
by	NULL
Glucocorticoids	NULL
through	NULL
Interference	NULL
with	NULL
Nuclear	NULL
Transcription	NULL
Factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
Fotini	NULL
Paliogianni	NULL
,	NULL
*	NULL
Anastasios	NULL
Raptis	NULL
,	NULL
*	NULL
Seema	NULL
S.	NULL
Ahuja	NULL
,	NULL
*	NULL
Sonia	NULL
M.	NULL
Najjar	NULL
,	NULL
*	NULL
and	NULL
Dimitrios	NULL
T.	NULL
Boumpas	NULL
*	NULL
*	NULL
Kidney	NULL
Disease	NULL
Section	NULL
and	NULL
*	NULL
Diabetes	NULL
Branch	NULL
,	NULL
National	NULL
Institute	NULL
of	NULL
Diabetes	NULL
and	NULL
Digestive	NULL
and	NULL
Kidney	NULL
Diseases	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
Maryland	NULL
20892	NULL
Abstract	NULL
IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
affected	NULL
by	NULL
several	NULL
nuclear	NULL
proteins	NULL
.	NULL

We	NULL
asked	NULL
whether	NULL
dexamethasone	NULL
(	NULL
Dex	NULL
)	NULL
and	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
nuclear	NULL
proteins	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
were	NULL
analyzed	NULL
by	NULL
electrophoretic	NULL
DNA	NULL
mobility	NULL
shift	NULL
assays	NULL
.	NULL

Both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
,	NULL
but	NULL
not	NULL
of	NULL
NF-kB	NULL
and	NULL
OCT-1/OAF	NULL
,	NULL
to	NULL
their	NULL
corresponding	NULL
sites	NULL
on	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
.	NULL

To	NULL
correlate	NULL
changes	NULL
in	NULL
nuclear	NULL
factor	NULL
binding	NULL
in	NULL
vitro	NULL
with	NULL
transcriptional	NULL
activity	NULL
in	NULL
vivo	NULL
and	NULL
define	NULL
the	NULL
structural	NULL
requirements	NULL
for	NULL
IL-2	NULL
promoter	NULL
repression	NULL
,	NULL
we	NULL
used	NULL
transient	NULL
DNA	NULL
transfections	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmids	NULL
containing	NULL
either	NULL
the	NULL
intact	NULL
IL-2	NULL
promoter	NULL
or	NULL
its	NULL
AP-1	NULL
,	NULL
NF-AT	NULL
,	NULL
and	NULL
NF-kB	NULL
motifs	NULL
.	NULL

Dex	NULL
inhibited	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
the	NULL
AP-1	NULL
,	NULL
but	NULL
not	NULL
the	NULL
NF-AT	NULL
and	NULL
NF-kB	NULL
plasmids	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
CsA	NULL
inhibited	NULL
the	NULL
IL-2	NULL
promoter	NULL
and	NULL
the	NULL
NF-AT	NULL
,	NULL
but	NULL
not	NULL
the	NULL
AP-1	NULL
and	NULL
NF-kB	NULL
plasmids	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
in	NULL
human	NULL
T	NULL
lymphocytes	NULL
both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibited	NULL
IL-2	NULL
gene	NULL
transcription	NULL
through	NULL
interference	NULL
with	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
,	NULL
while	NULL
maximum	NULL
inhibition	NULL
may	NULL
involve	NULL
interaction	NULL
with	NULL
both	NULL
transcription	NULL
factors	NULL
,	NULL
AP-1	NULL
is	NULL
the	NULL
primary	NULL
target	NULL
of	NULL
Dex	NULL
.	NULL

(	NULL
J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

1993	NULL
.	NULL

91:1481-1489	NULL
.	NULL
)	NULL

Key	NULL
words	NULL
:	NULL
glucocorticoids	NULL
»	NULL
interleukin	NULL
2	NULL
«	NULL
gene	NULL
transcription	NULL
«	NULL
nuclear	NULL
factor	NULL
AP-1	NULL
«	NULL
nuclear	NULL
factor	NULL
AT	NULL
Introduction	NULL
Glucocorticoids	NULL
(	NULL
GC	NULL
)	NULL
!	NULL

have	NULL
assumed	NULL
a	NULL
major	NULL
role	NULL
in	NULL
the	NULL
treatment	NULL
of	NULL
allograft	NULL
rejection	NULL
,	NULL
autoimmune	NULL
,	NULL
allergic	NULL
,	NULL
and	NULL
malignant	NULL
diseases	NULL
.	NULL

Their	NULL
widespread	NULL
use	NULL
is	NULL
based	NULL
on	NULL
their	NULL
profound	NULL
effects	NULL
on	NULL
inflammatory	NULL
and	NULL
immune	NULL
responses	NULL
.	NULL

GC	NULL
affect	NULL
the	NULL
growth	NULL
,	NULL
differentiation	NULL
,	NULL
and	NULL
function	NULL
of	NULL
monocytes	NULL
and	NULL
lymphocytes	NULL
,	NULL
the	NULL
distribution	NULL
of	NULL
cellular	NULL
subsets	NULL
,	NULL
and	NULL
cytokine	NULL
pro	NULL
Address	NULL
correspondence	NULL
to	NULL
Dr.	NULL
Fotini	NULL
Paliogianni	NULL
,	NULL
Kidney	NULL
Disease	NULL
Sec-tion	NULL
,	NULL
Building	NULL
10	NULL
,	NULL
Room	NULL
3N-114	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Be	NULL
thesda	NULL
,	NULL
MD	NULL
20892	NULL
.	NULL

Received	NULL
for	NULL
publication	NULL
2	NULL
July	NULL
1992	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
23	NULL
No	NULL
vember	NULL
1992	NULL
.	NULL

1	NULL
.	NULL

Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
Dex	NULL
,	NULL
dexamethasone	NULL
;	NULL
EMSA	NULL
,	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
;	NULL
GC	NULL
,	NULL
glu-cocorticoids	NULL
;	NULL
OAP	NULL
,	NULL
OCT	NULL
-1-associated	NULL
protein	NULL
;	NULL
PKC	NULL
,	NULL
protein	NULL
kinase	NULL
C	NULL
;	NULL
TRE	NULL
,	NULL
TPA-responsive	NULL
element	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Clinical	NULL
Investigation	NULL
,	NULL
Inc.	NULL
Volume	NULL
91	NULL
,	NULL
April	NULL
1993	NULL
,	NULL
1481-1489	NULL
duction	NULL
(	NULL
1	NULL
)	NULL
.	NULL

In	NULL
spite	NULL
of	NULL
their	NULL
widespread	NULL
medical	NULL
use	NULL
,	NULL
the	NULL
mechanism	NULL
of	NULL
their	NULL
inhibitory	NULL
effects	NULL
has	NULL
not	NULL
been	NULL
completely	NULL
de-fined	NULL
.	NULL

We	NULL
have	NULL
recently	NULL
reported	NULL
that	NULL
dexamethasone	NULL
(	NULL
Dex	NULL
)	NULL
,	NULL
a	NULL
synthetic	NULL
GC	NULL
hormone	NULL
,	NULL
inhibits	NULL
the	NULL
nuclear	NULL
transcription	NULL
of	NULL
IL-2	NULL
gene	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
(	NULL
2	NULL
)	NULL
.	NULL

IL-2	NULL
gene	NULL
transcription	NULL
is	NULL
mediated	NULL
by	NULL
a	NULL
region	NULL
extending	NULL
~	NULL
326	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
.	NULL

This	NULL
promoter	NULL
region	NULL
contains	NULL
binding	NULL
sites	NULL
for	NULL
at	NULL
least	NULL
seven	NULL
nuclear	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
;	NULL
references	NULL
3-9	NULL
)	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
has	NULL
not	NULL
revealed	NULL
any	NULL
cis-reacting	NULL
sequences	NULL
(	NULL
glucocorticoid	NULL
response	NULL
elements	NULL
,	NULL
GRE	NULL
)	NULL
for	NULL
binding	NULL
of	NULL
the	NULL
activated	NULL
GC	NULL
receptor	NULL
and	NULL
negative	NULL
transcriptional	NULL
regulation	NULL
(	NULL
10	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
delineation	NULL
of	NULL
the	NULL
mechanism	NULL
of	NULL
negative	NULL
transcriptional	NULL
regulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
has	NULL
been	NULL
the	NULL
subject	NULL
of	NULL
active	NULL
investigation	NULL
over	NULL
the	NULL
last	NULL
two	NULL
years	NULL
.	NULL

Even	NULL
though	NULL
several	NULL
recent	NULL
publications	NULL
have	NULL
explored	NULL
this	NULL
area	NULL
in	NULL
transformed	NULL
human	NULL
or	NULL
mouse	NULL
lymphocytes	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
,	NULL
the	NULL
mechanisms	NULL
of	NULL
GC-mediated	NULL
inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
remain	NULL
un-known	NULL
.	NULL

Using	NULL
electrophoretic	NULL
DNA	NULL
mobility	NULL
shift	NULL
assays	NULL
(	NULL
EMSA	NULL
)	NULL
and	NULL
transient	NULL
DNA	NULL
transfection	NULL
assays	NULL
,	NULL
we	NULL
have	NULL
examined	NULL
whether	NULL
interference	NULL
with	NULL
activity	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
IL-2	NULL
promoter	NULL
may	NULL
explain	NULL
the	NULL
inhibitory	NULL
effects	NULL
of	NULL
GC	NULL
on	NULL
IL-2	NULL
nuclear	NULL
transcription	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
the	NULL
effect	NULL
of	NULL
GC	NULL
on	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
we	NULL
have	NULL
also	NULL
examined	NULL
their	NULL
effect	NULL
on	NULL
transiently	NULL
transfected	NULL
transformed	NULL
T	NULL
lymphocytes	NULL
with	NULL
reporter	NULL
constructs	NULL
containing	NULL
specific	NULL
IL-2	NULL
promoter	NULL
motifs	NULL
and	NULL
have	NULL
compared	NULL
it	NULL
with	NULL
the	NULL
effect	NULL
of	NULL
another	NULL
unrelated	NULL
inhibitor	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
,	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
(	NULL
13-17	NULL
)	NULL
.	NULL

Our	NULL
data	NULL
suggest	NULL
that	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
GC	NULL
and	NULL
CsA	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
by	NULL
interfering	NULL
with	NULL
transcription	NULL
factors	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
.	NULL

Our	NULL
data	NULL
also	NULL
suggest	NULL
that	NULL
while	NULL
AP-1	NULL
is	NULL
the	NULL
primary	NULL
target	NULL
for	NULL
GC-mediated	NULL
repression	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
,	NULL
NF-AT	NULL
appears	NULL
to	NULL
be	NULL
the	NULL
main	NULL
target	NULL
of	NULL
CsA	NULL
action	NULL
.	NULL

Methods	NULL
Cell	NULL
cultures	NULL
.	NULL

Human	NULL
PBMC	NULL
were	NULL
obtained	NULL
and	NULL
purified	NULL
by	NULL
gradient	NULL
centrifugation	NULL
over	NULL
lymphocyte	NULL
separation	NULL
medium	NULL
(	NULL
Organon	NULL
Tek-nica	NULL
,	NULL
Durham	NULL
,	NULL
NC	NULL
)	NULL
from	NULL
leukapheresis	NULL
of	NULL
normal	NULL
volunteers	NULL
by	NULL
the	NULL
Department	NULL
of	NULL
Transfusion	NULL
Medicine	NULL
,	NULL
Clinical	NULL
Center	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
(	NULL
NIH	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
aspirated	NULL
from	NULL
the	NULL
resulting	NULL
interface	NULL
and	NULL
washed	NULL
three	NULL
times	NULL
in	NULL
PBS	NULL
without	NULL
Ca**	NULL
or	NULL
Mg**	NULL
.	NULL

PBMC	NULL
were	NULL
depleted	NULL
of	NULL
macrophages	NULL
by	NULL
fractionation	NULL
in	NULL
Sepracell-MN	NULL
(	NULL
Sepratech	NULL
,	NULL
Oklahoma	NULL
City	NULL
,	NULL
OK	NULL
)	NULL
,	NULL
according	NULL
to	NULL
the	NULL
instructions	NULL
of	NULL
the	NULL
manufac-turer	NULL
.	NULL

Monocyte-depleted	NULL
cells	NULL
were	NULL
collected	NULL
,	NULL
washed	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
ro-setted	NULL
with	NULL
2-aminoethyliso-thiouronium	NULL
bromide	NULL
pretreated	NULL
sheep	NULL
red	NULL
blood	NULL
cells	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
and	NULL
separated	NULL
over	NULL
lymphocyte	NULL
separation	NULL
medium	NULL
.	NULL

E	NULL
(	NULL
+	NULL
)	NULL
cells	NULL
were	NULL
resuspended	NULL
at	NULL
a	NULL
density	NULL
of	NULL
5	NULL
X	NULL
10°/ml	NULL
in	NULL
medium	NULL
consisting	NULL
of	NULL
RPMI	NULL
1640	NULL
(	NULL
Gibco	NULL
,	NULL
Mechanism	NULL
of	NULL
Immunosuppression	NULL
by	NULL
Glucocorticoids	NULL
__	NULL
1481	NULL
-257	NULL
-256	NULL
-	NULL
-2M42	NULL
-28	NULL
sw	NULL
OCT-1	NULL
-	NULL
188	NULL
-	NULL
~186	NULL
-177	NULL
-10	NULL
NF-AT	NULL
NF-xB	NULL
AP-1	NULL
-	NULL
164	NULL
-	NULL
146	NULL
-110	NULL
CD2BRC	NULL
AP-1	NULL
NRE-A	NULL
Figure	NULL
1	NULL
.	NULL

IL-2	NULL
promoter	NULL
with	NULL
known	NULL
protein	NULL
binding	NULL
sites	NULL
.	NULL

Numbers	NULL
at	NULL
the	NULL
top	NULL
represent	NULL
the	NULL
position	NULL
in	NULL
base	NULL
pairs	NULL
relative	NULL
to	NULL
the	NULL
initiation	NULL
of	NULL
transcription	NULL
site	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
the	NULL
other	NULL
motifs	NULL
,	NULL
which	NULL
upregulate	NULL
IL-2	NULL
expression	NULL
,	NULL
the	NULL
NRE-A	NULL
motif	NULL
binds	NULL
a	NULL
zinc	NULL
finger	NULL
protein	NULL
that	NULL
inhibits	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
9	NULL
)	NULL
.	NULL

(	NULL
Modified	NULL
from	NULL
reference	NULL
8	NULL
with	NULL
the	NULL
permission	NULL
of	NULL
the	NULL
American	NULL
Association	NULL
for	NULL
the	NULL
Advancement	NULL
of	NULL
Science	NULL
.	NULL
)	NULL

Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
and	NULL
25	NULL
ug/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
were	NULL
cultured	NULL
in	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
/95	NULL
%	NULL
air	NULL
at	NULL
37°C	NULL
for	NULL
various	NULL
times	NULL
with	NULL
1	NULL
ug/ml	NULL
ionomycin	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
10-30	NULL
ng/m	NULL
!	NULL

of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
PMA	NULL
,	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
,	NULL
M	NULL
Dex	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
and	NULL
100	NULL
to	NULL
1	NULL
ng/ml	NULL
of	NULL
CsA	NULL
(	NULL
Sandoz	NULL
,	NULL
Basel	NULL
,	NULL
Switzerland	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
preincubated	NULL
with	NULL
Dex	NULL
for	NULL
>	NULL
8	NULL
h	NULL
and	NULL
with	NULL
CsA	NULL
for	NULL
>	NULL
0.5	NULL
h	NULL
before	NULL
stimulation	NULL
.	NULL

Human	NULL
Jurkat	NULL
cells	NULL
were	NULL
cultured	NULL
in	NULL
RPMI-1	NULL
640	NULL
medium	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
heat-inactivated	NULL
FCS	NULL
,	NULL
25	NULL
ug/ml	NULL
gentamicin	NULL
,	NULL
and	NULL
5	NULL
x	NULL
10	NULL
~	NULL
'	NULL
M	NULL
2-mercaptocth-anol	NULL
(	NULL
Sigma	NULL
Chemical	NULL
Co.	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
prepared	NULL
from	NULL
2	NULL
x	NULL
10°	NULL
T-lymphocytes	NULL
by	NULL
a	NULL
modification	NULL
of	NULL
the	NULL
method	NULL
of	NULL
Dignam	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
cells	NULL
were	NULL
washed	NULL
once	NULL
with	NULL
PBS	NULL
and	NULL
twice	NULL
with	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
Hepes	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KCl	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
20	NULL
al	NULL
of	NULL
buffer	NULL
A/0.1	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
incubated	NULL
10	NULL
min	NULL
on	NULL
ice	NULL
,	NULL
mixed	NULL
briefly	NULL
,	NULL
and	NULL
spun	NULL
in	NULL
a	NULL
microcentrifuge	NULL
(	NULL
full	NULL
speed	NULL
)	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
removed	NULL
and	NULL
the	NULL
nuclear	NULL
pellet	NULL
was	NULL
suspended	NULL
in	NULL
20	NULL
ul	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
25	NULL
%	NULL
glycerol	NULL
,	NULL
0.42	NULL
M	NULL
KCI	NULL
,	NULL
1.5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
)	NULL
,	NULL
incubated	NULL
15	NULL
min	NULL
at	NULL
4°C	NULL
,	NULL
mixed	NULL
briefly	NULL
,	NULL
and	NULL
microcentrifuged	NULL
for	NULL
10	NULL
min	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
supernatant	NULL
was	NULL
diluted	NULL
with	NULL
equal	NULL
volume	NULL
of	NULL
modified	NULL
buffer	NULL
D	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
20	NULL
%	NULL
glycerol	NULL
,	NULL
0.2	NULL
mM	NULL
EDTA	NULL
,	NULL
0.5	NULL
mM	NULL
PMSF	NULL
,	NULL
0.5	NULL
mM	NULL
DTT	NULL
)	NULL
(	NULL
18	NULL
)	NULL
.	NULL

The	NULL
protein	NULL
concentration	NULL
in	NULL
the	NULL
nuclear	NULL
extracts	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
19	NULL
)	NULL
.	NULL

DNA-protein	NULL
binding	NULL
assay	NULL
.	NULL

End-labeled	NULL
DNA	NULL
fragments	NULL
(	NULL
0.2-0.5	NULL
ng	NULL
,	NULL
~	NULL
2	NULL
X	NULL
10°	NULL
)	NULL
cpm	NULL
were	NULL
incubated	NULL
at	NULL
room	NULL
temperature	NULL
for	NULL
30	NULL
min	NULL
with	NULL
5	NULL
to	NULL
10	NULL
Lg	NULL
of	NULL
nuclear	NULL
protein	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
4	NULL
ug	NULL
poly-dI-dC	NULL
in	NULL
15	NULL
l	NULL
of	NULL
buffer	NULL
.	NULL

Two	NULL
buffers	NULL
were	NULL
used	NULL
:	NULL
Buffer	NULL
I	NULL
(	NULL
10	NULL
mM	NULL
Tris	NULL
HCl	NULL
,	NULL
pH	NULL
7.5	NULL
;	NULL
50	NULL
mM	NULL
NaCl	NULL
;	NULL
1	NULL
mM	NULL
DDT	NULL
;	NULL
and	NULL
5	NULL
%	NULL
glycerol	NULL
)	NULL
was	NULL
used	NULL
for	NULL
NF-kB	NULL
and	NULL
NF-AT	NULL
EMSA	NULL
.	NULL

Buffer	NULL
II	NULL
(	NULL
20	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.9	NULL
;	NULL
2.5	NULL
mM	NULL
MgC	NULL
)	NULL
;	NULL
;	NULL
40	NULL
mM	NULL
KCI	NULL
;	NULL
1	NULL
mM	NULL
DTT	NULL
;	NULL
and	NULL
4	NULL
%	NULL
Ficoll	NULL
)	NULL
was	NULL
used	NULL
for	NULL
AP-1	NULL
and	NULL
OCT-1	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
probe	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.25	NULL
%	NULL
Tris	NULL
borate	NULL
buffer	NULL
at	NULL
150	NULL
V	NULL
for	NULL
1.5	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

The	NULL
gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
determined	NULL
by	NULL
using	NULL
20-fold	NULL
excess	NULL
of	NULL
specific	NULL
cold	NULL
oligonucleotide	NULL
,	NULL
which	NULL
competed	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
proteins	NULL
to	NULL
radiolabeled	NULL
probe	NULL
,	NULL
whereas	NULL
a	NULL
similar	NULL
excess	NULL
of	NULL
unrelated	NULL
oligonucleotide	NULL
did	NULL
not	NULL
compete	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
binding	NULL
of	NULL
proteins	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
contained	NULL
c-Jun	NULL
or	NULL
c-	NULL
fos	NULL
protein	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
0.1	NULL
ug	NULL
of	NULL
purified	NULL
c-jun	NULL
rabbit	NULL
polyclonal	NULL
IgG	NULL
antibody	NULL
against	NULL
the	NULL
DNA	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
protein	NULL
(	NULL
Oncogene	NULL
Science	NULL
,	NULL
Inc.	NULL
,	NULL
Uniondale	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
1	NULL
ul	NULL
of	NULL
anti-jun	NULL
antibody	NULL
636/5	NULL
provided	NULL
by	NULL
Dr.	NULL
R.	NULL
Bravo	NULL
(	NULL
Bristol-Myers	NULL
,	NULL
Squibb	NULL
Institute	NULL
,	NULL
Princeton	NULL
,	NULL
NJ	NULL
)	NULL
(	NULL
20	NULL
)	NULL
,	NULL
0.1	NULL
ug	NULL
of	NULL
purified	NULL
anti-	NULL
fos	NULL
rabbit	NULL
polyclonal	NULL
antibody	NULL
against	NULL
the	NULL
NH	NULL
-terminal	NULL
domain	NULL
of	NULL
c-fos	NULL
(	NULL
Oncogene	NULL
Science	NULL
)	NULL
,	NULL
or	NULL
0.1	NULL
ug	NULL
normal	NULL
rabbit	NULL
immunoglobulin	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
labeled	NULL
AP-1	NULL
probe	NULL
.	NULL

DNA	NULL
probes	NULL
.	NULL

The	NULL
oligonucleotides	NULL
were	NULL
synthesized	NULL
with	NULL
a	NULL
DNA	NULL
synthesizer	NULL
(	NULL
Applied	NULL
Biosystems	NULL
;	NULL
Foster	NULL
City	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Complementary	NULL
sequences	NULL
were	NULL
annealed	NULL
at	NULL
68°C	NULL
for	NULL
10	NULL
min	NULL
and	NULL
then	NULL
cooled	NULL
to	NULL
room	NULL
temperature	NULL
,	NULL
labeled	NULL
with	NULL
[	NULL
*P	NULL
]	NULL
ATP	NULL
,	NULL
and	NULL
used	NULL
for	NULL
EMSA	NULL
after	NULL
gel	NULL
puri-fication	NULL
.	NULL

The	NULL
following	NULL
probes	NULL
were	NULL
used	NULL
,	NULL
all	NULL
derived	NULL
from	NULL
sequences	NULL
present	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
region	NULL
:	NULL
For	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
-157	NULL
to	NULL
-140	NULL
'TTCCAAAGAGTCATCAG	NULL
'	NULL
;	NULL
NF-AT	NULL
binding	NULL
site	NULL
sequences	NULL
-285	NULL
to	NULL
-254	NULL
,	NULL
'GGAGGAAAAACTGTTTCATACAGAAG-GCGT®	NULL
;	NULL
OCT-1	NULL
binding	NULL
site	NULL
from	NULL
-82	NULL
to	NULL
-67	NULL
,	NULL
'TAATATGTAAAA-	NULL
CATT	NULL
}	NULL
;	NULL
and	NULL
NF-kB	NULL
binding	NULL
site	NULL
from	NULL
-206	NULL
to	NULL
-	NULL
195	NULL
,	NULL
'GGGATTTCA-CCT	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Plasmids	NULL
.	NULL

The	NULL
plasmid	NULL
pIL-2	NULL
CAT	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
U.	NULL
Siebenlist	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
,	NULL
Bethesda	NULL
,	NULL
MD	NULL
)	NULL
contains	NULL
632	NULL
bp	NULL
of	NULL
the	NULL
5-flanking	NULL
sequences	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
gene	NULL
,	NULL
including	NULL
575	NULL
bp	NULL
upstream	NULL
of	NULL
the	NULL
transcription	NULL
start	NULL
site	NULL
through	NULL
position	NULL
+57	NULL
bp	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
22	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
AP-1	NULL
CAT	NULL
(	NULL
TRE-tk	NULL
CAT	NULL
,	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
M.	NULL
Karin	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
La	NULL
Jolla	NULL
,	NULL
CA	NULL
)	NULL
contains	NULL
a	NULL
synthetic	NULL
oligonucleotide	NULL
from	NULL
-7	NULL
1	NULL
to	NULL
-65	NULL
of	NULL
the	NULL
human	NULL
collagenase	NULL
gene	NULL
flanked	NULL
by	NULL
HindIII/Bam	NULL
linker	NULL
sequences	NULL
cloned	NULL
into	NULL
HindIII	NULL
/	NULL
BamHI	NULL
cut	NULL
of	NULL
pBLCAT2	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
(	NULL
HSV	NULL
-tk	NULL
)	NULL
promoter	NULL
from	NULL
position	NULL
-109	NULL
to	NULL
+51	NULL
in	NULL
front	NULL
of	NULL
the	NULL
CAT	NULL
structural	NULL
gene	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
NF-AT	NULL
CAT	NULL
plasmid	NULL
(	NULL
a	NULL
gift	NULL
from	NULL
Dr.	NULL
G.	NULL
Crabtree	NULL
,	NULL
Stanford	NULL
University	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
)	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
NF-AT	NULL
binding	NULL
site	NULL
containing	NULL
5°	NULL
IL-2	NULL
sequences	NULL
-255	NULL
to	NULL
-285	NULL
linked	NULL
to	NULL
the	NULL
IL-2	NULL
promoter	NULL
sequences	NULL
from	NULL
-72	NULL
to	NULL
+47	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
7	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
NF-Kb	NULL
(	NULL
provided	NULL
by	NULL
Dr.	NULL
U.	NULL
Siebenlist	NULL
)	NULL
contains	NULL
the	NULL
kB	NULL
site	NULL
from	NULL
the	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
minimal	NULL
c-	NULL
fos	NULL
promoter	NULL
inserted	NULL
at	NULL
the	NULL
Sal	NULL
site	NULL
at	NULL
-56	NULL
,	NULL
and	NULL
drives	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
24	NULL
)	NULL
.	NULL

The	NULL
plasmid	NULL
pCH110	NULL
(	NULL
Pharmacia	NULL
Inc.	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
contains	NULL
a	NULL
functional	NULL
lacZ	NULL
gene	NULL
,	NULL
coding	NULL
for	NULL
-galactosidase	NULL
,	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
the	NULL
SV40	NULL
early	NULL
promoter	NULL
.	NULL

DNA	NULL
transfections	NULL
.	NULL

Transfections	NULL
of	NULL
lymphoid	NULL
cells	NULL
were	NULL
carried	NULL
out	NULL
by	NULL
the	NULL
DEAE-dextran	NULL
method	NULL
(	NULL
4	NULL
)	NULL
.	NULL

To	NULL
decrease	NULL
variations	NULL
in	NULL
transfection	NULL
efficiency	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
in	NULL
single	NULL
batches	NULL
,	NULL
which	NULL
were	NULL
then	NULL
separated	NULL
into	NULL
different	NULL
drug	NULL
treatment	NULL
groups	NULL
.	NULL

As	NULL
an	NULL
internal	NULL
marker	NULL
for	NULL
monitoring	NULL
and	NULL
normalizing	NULL
transient	NULL
expression	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
pCH110	NULL
.	NULL

For	NULL
each	NULL
treatment	NULL
,	NULL
1.5-2	NULL
x	NULL
10	NULL
cells	NULL
harvested	NULL
in	NULL
log	NULL
phase	NULL
of	NULL
growth	NULL
(	NULL
3-5	NULL
x	NULL
10°	NULL
cells/ml	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
20	NULL
ug	NULL
DNA	NULL
and	NULL
100	NULL
ug/ml	NULL
DEAE-dextran	NULL
in	NULL
serum-free	NULL
RPMI-1640	NULL
medium	NULL
for	NULL
50	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
two	NULL
washes	NULL
with	NULL
serum-free	NULL
RPMI-1640	NULL
medium	NULL
they	NULL
were	NULL
replated	NULL
in	NULL
complete	NULL
medium	NULL
.	NULL

24	NULL
h	NULL
after	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
Dex	NULL
>	NULL
8	NULL
h	NULL
and	NULL
for	NULL
0.5	NULL
h	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
CsA	NULL
.	NULL

Then	NULL
they	NULL
were	NULL
stimulated	NULL
for	NULL
8	NULL
h	NULL
with	NULL
ionomycin	NULL
1	NULL
ug/ml	NULL
and	NULL
30	NULL
ng/ml	NULL
of	NULL
PMA	NULL
.	NULL

After	NULL
stimulation	NULL
,	NULL
cells	NULL
were	NULL
harvested	NULL
and	NULL
extracts	NULL
were	NULL
prepared	NULL
by	NULL
rapid	NULL
freeze-thawing	NULL
.	NULL

Protein	NULL
concentration	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
19	NULL
)	NULL
and	NULL
equivalent	NULL
amounts	NULL
of	NULL
protein	NULL
extracts	NULL
were	NULL
assayed	NULL
for	NULL
enzyme	NULL
activity	NULL
.	NULL

CAT	NULL
assay	NULL
.	NULL

CAT	NULL
assay	NULL
was	NULL
carried	NULL
out	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
25	NULL
)	NULL
by	NULL
incubation	NULL
of	NULL
50	NULL
ug	NULL
of	NULL
cell	NULL
lysate	NULL
protein	NULL
with	NULL
0.1	NULL
LCi	NULL
of	NULL
[	NULL
``	NULL
CJ	NULL
)	NULL
-chloramphenicol	NULL
(	NULL
specific	NULL
activity	NULL
57.3	NULL
mg/mmol	NULL
,	NULL
NEN	NULL
Research	NULL
Products	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
9	NULL
mM	NULL
acetyl-coenzyme	NULL
A	NULL
(	NULL
Pharmacia	NULL
Inc.	NULL
)	NULL
for	NULL
3	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

Acetylated	NULL
and	NULL
unacetylated	NULL
chloramphenicol	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
layer	NULL
chromatography	NULL
,	NULL
and	NULL
acetyla-tion	NULL
quantified	NULL
by	NULL
autoradiography	NULL
.	NULL

B-galactosidase	NULL
assay	NULL
.	NULL

Equal	NULL
amounts	NULL
of	NULL
the	NULL
same	NULL
cell	NULL
lysate	NULL
used	NULL
for	NULL
CAT	NULL
assays	NULL
were	NULL
diluted	NULL
in	NULL
100	NULL
mM	NULL
NaPO	NULL
,	NULL
,	NULL
10	NULL
mM	NULL
KCl	NULL
,	NULL
1	NULL
mM	NULL
MgSo	NULL
,	NULL
,	NULL
50	NULL
mM	NULL
2-mercaptoethanol	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
and	NULL
-galactosidase	NULL
activity	NULL
was	NULL
determined	NULL
spectrophotometrically	NULL
at	NULL
420	NULL
nm	NULL
by	NULL
the	NULL
hydrolysis	NULL
of	NULL
o-nitrophenol-8-p-galactoside	NULL
.	NULL

Results	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
protein	NULL
kinase	NULL
C-	NULL
and	NULL
calcium-me-diated	NULL
trans-activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
nuclear	NULL
transcription	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
gene	NULL
(	NULL
2	NULL
,	NULL
1482	NULL
F.	NULL
Paliogianni	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.	NULL
S.	NULL
Ahuja	NULL
,	NULL
S.	NULL
M.	NULL
Najjar	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
13-17	NULL
)	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
their	NULL
inhibition	NULL
is	NULL
mediated	NULL
through	NULL
interference	NULL
with	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
,	NULL
Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
(	NULL
p	NULL
)	NULL
IL-2	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
IL-2	NULL
promoter	NULL
region	NULL
driving	NULL
the	NULL
expression	NULL
of	NULL
CAT	NULL
gene	NULL
(	NULL
see	NULL
Methods	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
Dex	NULL
(	NULL
10-10	NULL
~	NULL
M	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
1,000	NULL
to	NULL
0.1	NULL
ng/ml	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
(	NULL
1	NULL
ug/ml	NULL
)	NULL
and	NULL
PMA	NULL
(	NULL
30	NULL
ng/ml	NULL
)	NULL
.	NULL

18	NULL
h	NULL
later	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

pIL-2	NULL
CAT	NULL
was	NULL
not	NULL
expressed	NULL
in	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
or	NULL
in	NULL
cells	NULL
incubated	NULL
with	NULL
Dex	NULL
or	NULL
CsA	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
significantly	NULL
increased	NULL
CAT	NULL
activity	NULL
.	NULL

Both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibited	NULL
the	NULL
expression	NULL
of	NULL
IL-2	NULL
CAT	NULL
after	NULL
stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
in	NULL
a	NULL
dose-dependent	NULL
fashion	NULL
(	NULL
minimum	NULL
effective	NULL
dose	NULL
10	NULL
~	NULL
'	NULL
M	NULL
and	NULL
0.1	NULL
ng/ml	NULL
respectively	NULL
,	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Dex	NULL
at	NULL
the	NULL
dose	NULL
of	NULL
10~°	NULL
M	NULL
inhibited	NULL
by	NULL
a	NULL
mean	NULL
of	NULL
60	NULL
%	NULL
(	NULL
range	NULL
54-67	NULL
%	NULL
)	NULL
the	NULL
CAT	NULL
activity	NULL
(	NULL
three	NULL
different	NULL
experiments	NULL
)	NULL
,	NULL
whereas	NULL
at	NULL
10~	NULL
'	NULL
M	NULL
inhibition	NULL
was	NULL
~	NULL
20	NULL
%	NULL
(	NULL
range	NULL
15-28	NULL
%	NULL
)	NULL
.	NULL

Inhibition	NULL
by	NULL
CsA	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
1,000-10	NULL
ng/ml	NULL
,	NULL
100	NULL
%	NULL
;	NULL
1	NULL
ng	NULL
,	NULL
~	NULL
80	NULL
%	NULL
,	NULL
0.5	NULL
ng	NULL
,	NULL
~	NULL
40	NULL
%	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
by	NULL
interfering	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
IL-2	NULL
promoter	NULL
,	NULL
and	NULL
that	NULL
CsA	NULL
is	NULL
more	NULL
potent	NULL
than	NULL
Dex	NULL
(	NULL
on	NULL
a	NULL
molar	NULL
to	NULL
molar	NULL
basis	NULL
)	NULL
in	NULL
mediating	NULL
this	NULL
inhibition	NULL
.	NULL

Stimulation	NULL
through	NULL
ionomycin	NULL
and	NULL
PMA	NULL
induces	NULL
the	NULL
activity	NULL
of	NULL
nuclear	NULL
proteins	NULL
AT	NULL
,	NULL
NF-kB	NULL
,	NULL
AP-1	NULL
and	NULL
OCT	NULL
/OAP	NULL
,	NULL
all	NULL
of	NULL
which	NULL
are	NULL
thought	NULL
to	NULL
contribute	NULL
to	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
IL-2	NULL
promoter	NULL
in	NULL
various	NULL
degrees	NULL
(	NULL
7	NULL
,	NULL
9	NULL
,	NULL
26	NULL
,	NULL
27	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
have	NULL
suggested	NULL
a	NULL
functional	NULL
antagonism	NULL
between	NULL
the	NULL
AP-1	NULL
transcriptional	NULL
factor	NULL
for	NULL
the	NULL
collagenase	NULL
gene	NULL
and	NULL
the	NULL
activated	NULL
GR	NULL
(	NULL
28-30	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
first	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
Dex	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
stimulated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
inhibited	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

Common	NULL
to	NULL
many	NULL
genes	NULL
in	NULL
which	NULL
transcription	NULL
is	NULL
induced	NULL
by	NULL
the	NULL
phorbol	NULL
ester	NULL
TPA	NULL
is	NULL
a	NULL
con	NULL
IL-2	NULL
CAT	NULL
T	NULL
*It	NULL
?	NULL

#	NULL
[	NULL
#	NULL
&	NULL
%	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
_	NULL
-	NULL
-	NULL
+	NULL
+	NULL
+	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
Dex	NULL
.	NULL

10	NULL
-6m	NULL
_-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
CsA	NULL
Dex	NULL
.	NULL

10	NULL
~	NULL
``	NULL
M	NULL
_	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
Q	NULL
’	NULL
Q	NULL
.	NULL

served	NULL
sequence	NULL
TGAGTCA	NULL
functioning	NULL
as	NULL
a	NULL
TPA	NULL
responsive	NULL
element	NULL
(	NULL
TRE	NULL
)	NULL
.	NULL

This	NULL
sequence	NULL
is	NULL
recognized	NULL
by	NULL
the	NULL
transcriptional	NULL
factor	NULL
AP-1	NULL
,	NULL
which	NULL
is	NULL
encoded	NULL
by	NULL
the	NULL
cellular	NULL
proto-oncogene	NULL
c-jun	NULL
(	NULL
31-34	NULL
)	NULL
.	NULL

c-fos	NULL
protein	NULL
interacts	NULL
with	NULL
AP-1	NULL
through	NULL
their	NULL
``	NULL
leucine	NULL
zipper	NULL
.	NULL
``	NULL

This	NULL
complex	NULL
binds	NULL
to	NULL
the	NULL
TRE	NULL
with	NULL
an	NULL
affinity	NULL
300-fold	NULL
higher	NULL
than	NULL
AP-1	NULL
alone	NULL
,	NULL
leading	NULL
to	NULL
transactivation	NULL
of	NULL
AP-1-dependent	NULL
transcription	NULL
(	NULL
34	NULL
)	NULL
.	NULL

The	NULL
human	NULL
IL-2	NULL
promoter	NULL
contains	NULL
two	NULL
TREs	NULL
,	NULL
one	NULL
proximal	NULL
and	NULL
one	NULL
distal	NULL
.	NULL

Footprint	NULL
and	NULL
deletion	NULL
analysis	NULL
has	NULL
shown	NULL
that	NULL
only	NULL
proximal	NULL
TRE	NULL
binds	NULL
strongly	NULL
AP-1	NULL
and	NULL
has	NULL
revealed	NULL
its	NULL
importance	NULL
in	NULL
IL-2	NULL
enhancer	NULL
activity	NULL
(	NULL
7-9	NULL
)	NULL
.	NULL

Human	NULL
peripheral	NULL
blood	NULL
T	NULL
lymphocytes	NULL
were	NULL
therefore	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
after	NULL
preincubation	NULL
with	NULL
Dex	NULL
(	NULL
>	NULL
8	NULL
h	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
0.5	NULL
h	NULL
)	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
16	NULL
h	NULL
later	NULL
and	NULL
analyzed	NULL
in	NULL
an	NULL
EMSA	NULL
using	NULL
end-labeled	NULL
DNA	NULL
fragment	NULL
corresponding	NULL
to	NULL
the	NULL
proximal	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
enhancer	NULL
.	NULL

In	NULL
agreement	NULL
with	NULL
previous	NULL
observations	NULL
(	NULL
21	NULL
)	NULL
,	NULL
unstimulated	NULL
T	NULL
lymphocytes	NULL
contain	NULL
little	NULL
or	NULL
no	NULL
AP-1	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
these	NULL
cells	NULL
effectively	NULL
induced	NULL
AP-1	NULL
activity	NULL
.	NULL

The	NULL
sequence	NULL
specificity	NULL
of	NULL
the	NULL
binding	NULL
was	NULL
assessed	NULL
by	NULL
using	NULL
molar	NULL
excess	NULL
of	NULL
homolo-gous	NULL
and	NULL
heterologous	NULL
oligonucleotide	NULL
as	NULL
competitors	NULL
.	NULL

Protein	NULL
binding	NULL
to	NULL
the	NULL
P-labeled	NULL
IL-2	NULL
AP-1	NULL
site	NULL
was	NULL
inhibited	NULL
by	NULL
a	NULL
cold	NULL
homologous	NULL
,	NULL
but	NULL
not	NULL
with	NULL
a	NULL
heterologous	NULL
(	NULL
NF-kB	NULL
)	NULL
oligonucleotide	NULL
(	NULL
see	NULL
Methods	NULL
)	NULL
.	NULL

An	NULL
antibody	NULL
raised	NULL
against	NULL
a	NULL
peptide	NULL
common	NULL
to	NULL
the	NULL
DNA-binding	NULL
region	NULL
of	NULL
Jun	NULL
proteins	NULL
,	NULL
but	NULL
not	NULL
an	NULL
equivalent	NULL
concentration	NULL
of	NULL
normal	NULL
rabbit	NULL
immunoglobulin	NULL
,	NULL
specifically	NULL
blocked	NULL
protein	NULL
binding	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
contains	NULL
Jun	NULL
protein	NULL
and	NULL
identifying	NULL
it	NULL
as	NULL
the	NULL
AP-1	NULL
factor	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
B	NULL
)	NULL
.	NULL

An	NULL
antibody	NULL
raised	NULL
against	NULL
c-fos	NULL
decreased	NULL
the	NULL
mobility	NULL
of	NULL
this	NULL
complex	NULL
,	NULL
suggesting	NULL
that	NULL
it	NULL
contains	NULL
c-fos	NULL
protein	NULL
.	NULL

Both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibited	NULL
the	NULL
formation	NULL
of	NULL
the	NULL
AP-1	NULL
complex	NULL
.	NULL

Lower	NULL
concentration	NULL
of	NULL
Dex	NULL
(	NULL
107	NULL
'	NULL
M	NULL
)	NULL
had	NULL
little	NULL
effect	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
4	NULL
)	NULL
,	NULL
whereas	NULL
10	NULL
~	NULL
M	NULL
had	NULL
no	NULL
effect	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
AP-1	NULL
transcription	NULL
factor	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
pro	NULL
moter	NULL
.	NULL

Figure	NULL
2	NULL
.	NULL

Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
Ca	NULL
``	NULL
*	NULL
and	NULL
PKC-mediated	NULL
trans-activation	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
IL-2	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
IL-2	NULL
promoter	NULL
driving	NULL
that	NULL
.	NULL

expression	NULL
of	NULL
CAT	NULL
gene	NULL
(	NULL
see	NULL
Methods	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
Dex	NULL
(	NULL
10°	NULL
or	NULL
10~	NULL
'	NULL
«	NULL
e	NULL
M	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
and	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

18	NULL
h	NULL
later	NULL
,	NULL
cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

To	NULL
decrease	NULL
variations	NULL
in	NULL
transfection	NULL
efficiency	NULL
,	NULL
cells	NULL
were	NULL
transfected	NULL
in	NULL
single	NULL
batches	NULL
,	NULL
which	NULL
were	NULL
then	NULL
separated	NULL
into	NULL
different	NULL
drug	NULL
treatment	NULL
groups	NULL
.	NULL

pCH110	NULL
(	NULL
which	NULL
contains	NULL
functional	NULL
lacZ	NULL
gene	NULL
,	NULL
coding	NULL
for	NULL
$	NULL
-galactosidase	NULL
)	NULL
was	NULL
used	NULL
as	NULL
an	NULL
inter-+	NULL
nal	NULL
marker	NULL
for	NULL
monitoring	NULL
and	NULL
normalizing	NULL
transient	NULL
transfections	NULL
.	NULL

Acetylated	NULL
and	NULL
unacetylated	NULL
chloramphenicol	NULL
were	NULL
separated	NULL
by	NULL
thin	NULL
#	NULL
#	NULL
#	NULL
layer	NULL
chromatography	NULL
and	NULL
quantified	NULL
by	NULL
autoradiography	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

During	NULL
this	NULL
experiment	NULL
inhibition	NULL
of	NULL
IL-2	NULL
CAT	NULL
activity	NULL
by	NULL
CsA	NULL
was	NULL
100	NULL
%	NULL
,	NULL
whereas	NULL
for	NULL
Dex	NULL
10	NULL
~®	NULL
M	NULL
and	NULL
10~	NULL
'	NULL
M	NULL
it	NULL
was	NULL
67	NULL
and	NULL
28	NULL
%	NULL
,	NULL
respectively	NULL
.	NULL

Mechanism	NULL
of	NULL
Immunosuppression	NULL
by	NULL
Glucocorticoids	NULL
__	NULL
1483	NULL
S	NULL
ax	NULL
a	NULL
&	NULL
x	NULL
a	NULL
§	NULL
8	NULL
8®8_	NULL
¢s	NULL
&	NULL
>	NULL
$	NULL
_	NULL
2C	NULL
F	NULL
2	NULL
2	NULL
*	NULL
9	NULL
2	NULL
o	NULL
©	NULL
&	NULL
G	NULL
0	NULL
4	NULL
§	NULL
éQ®\°	NULL
$	NULL
Q	NULL
>	NULL
<	NULL
Q	NULL
>	NULL
<	NULL
Qo	NULL
(	NULL
JOQK	NULL
\§v	NULL
<	NULL
$	NULL
it	NULL
sense	NULL
AP-1	NULL
Figure	NULL
3	NULL
.	NULL

(	NULL
A	NULL
)	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
stimulated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
to	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

In	NULL
EMSA	NULL
a	NULL
**P-end-labeled	NULL
17-bp	NULL
DNA	NULL
probe	NULL
that	NULL
included	NULL
the	NULL
AP-1	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
was	NULL
incubated	NULL
with	NULL
nuclear	NULL
extracts	NULL
(	NULL
10	NULL
ug/lane	NULL
)	NULL
prepared	NULL
from	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
resting	NULL
or	NULL
stimulated	NULL
,	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
or	NULL
CsA	NULL
for	NULL
16	NULL
h	NULL
,	NULL
in	NULL
buffer	NULL
II	NULL
(	NULL
see	NULL
Methods	NULL
)	NULL
.	NULL

Protein-DNA	NULL
complexes	NULL
were	NULL
separated	NULL
from	NULL
free	NULL
probe	NULL
on	NULL
a	NULL
5	NULL
%	NULL
polyacrylamide	NULL
gel	NULL
in	NULL
0.25	NULL
x	NULL
Tris	NULL
borate	NULL
buffer	NULL
.	NULL

Gels	NULL
were	NULL
dried	NULL
and	NULL
exposed	NULL
to	NULL
x-ray	NULL
film	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
determined	NULL
by	NULL
the	NULL
use	NULL
of	NULL
a	NULL
20-fold	NULL
excess	NULL
of	NULL
specific	NULL
or	NULL
unrelated	NULL
oligonucleotide	NULL
.	NULL

(	NULL
B	NULL
)	NULL
To	NULL
determine	NULL
whether	NULL
the	NULL
binding	NULL
proteins	NULL
contain	NULL
c-jun	NULL
and	NULL
c-fos	NULL
protein	NULL
,	NULL
nuclear	NULL
extracts	NULL
from	NULL
stimulated	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
0	NULL
.	NULL

1	NULL
ug	NULL
of	NULL
affinity	NULL
purified	NULL
c-jun	NULL
(	NULL
«	NULL
Jun	NULL
)	NULL
or	NULL
c-	NULL
fos	NULL
(	NULL
«	NULL
fos	NULL
)	NULL
antibodies	NULL
,	NULL
or	NULL
0.1	NULL
ug	NULL
of	NULL
normal	NULL
rabbit	NULL
immunoglobulin	NULL
(	NULL
RZ	NULL
)	NULL
before	NULL
addition	NULL
of	NULL
the	NULL
labeled	NULL
AP-1	NULL
probe	NULL
.	NULL

a	NULL
Jun	NULL
binds	NULL
to	NULL
the	NULL
DNA	NULL
binding	NULL
site	NULL
of	NULL
the	NULL
protein	NULL
,	NULL
thus	NULL
inhibiting	NULL
its	NULL
binding	NULL
.	NULL

The	NULL
``	NULL
supershift	NULL
``	NULL
observed	NULL
with	NULL
«	NULL
Fos	NULL
is	NULL
consistent	NULL
with	NULL
this	NULL
antibody	NULL
binding	NULL
to	NULL
the	NULL
Jun-Fos	NULL
complex	NULL
,	NULL
thus	NULL
decreasing	NULL
its	NULL
mobility	NULL
.	NULL

Dex	NULL
but	NULL
not	NULL
CsA	NULL
inhibits	NULL
the	NULL
in	NULL
vivo	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
construct	NULL
containing	NULL
the	NULL
AP-1	NULL
site	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transfected	NULL
with	NULL
plasmid	NULL
AP-1	NULL
CAT	NULL
(	NULL
TRE-CAT	NULL
)	NULL
,	NULL
which	NULL
contains	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
collagenase	NULL
gene	NULL
cloned	NULL
into	NULL
pBLCAT2	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
preincubated	NULL
with	NULL
Dex	NULL
(	NULL
10	NULL
~*-10~	NULL
M	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
10-1,000	NULL
ng/ml	NULL
)	NULL
as	NULL
described	NULL
in	NULL
Methods	NULL
and	NULL
stimulated	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

Cell	NULL
extracts	NULL
were	NULL
prepared	NULL
and	NULL
assayed	NULL
8	NULL
,	NULL
18	NULL
,	NULL
and	NULL
36	NULL
h	NULL
later	NULL
.	NULL

Unstimulated	NULL
Jurkat	NULL
cells	NULL
expressed	NULL
low	NULL
but	NULL
detectable	NULL
AP-1	NULL
CAT	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
suppressed	NULL
by	NULL
Dex	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Dex	NULL
,	NULL
CsA	NULL
failed	NULL
to	NULL
suppress	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
construct	NULL
.	NULL

As	NULL
expected	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
,	NULL
activity	NULL
of	NULL
AP-1	NULL
CAT	NULL
was	NULL
induced	NULL
by	NULL
severalfold	NULL
.	NULL

Dex	NULL
inhibited	NULL
the	NULL
inducible	NULL
activity	NULL
of	NULL
AP-1	NULL
CAT	NULL
by	NULL
a	NULL
mean	NULL
of	NULL
~	NULL
70	NULL
%	NULL
(	NULL
range	NULL
60-80	NULL
%	NULL
)	NULL
at	NULL
10~°	NULL
M	NULL
and	NULL
~	NULL
30	NULL
%	NULL
(	NULL
range	NULL
35-25	NULL
%	NULL
)	NULL
at	NULL
10~	NULL
``	NULL
M	NULL
,	NULL
when	NULL
cells	NULL
1484	NULL
were	NULL
harvested	NULL
at	NULL
18	NULL
h.	NULL
Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
cells	NULL
were	NULL
harvested	NULL
at	NULL
8-	NULL
and	NULL
36-h	NULL
time	NULL
points	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Lower	NULL
doses	NULL
of	NULL
Dex	NULL
(	NULL
10	NULL
~	NULL
M	NULL
)	NULL
did	NULL
not	NULL
have	NULL
a	NULL
significant	NULL
effect	NULL
on	NULL
AP-1	NULL
CAT	NULL
activity	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Dex	NULL
,	NULL
CsA	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
inducible	NULL
activity	NULL
of	NULL
AP-1	NULL
CAT	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
at	NULL
concentrations	NULL
that	NULL
were	NULL
previously	NULL
found	NULL
to	NULL
be	NULL
effective	NULL
for	NULL
downreg-ulation	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
.	NULL

Concentrations	NULL
of	NULL
CsA	NULL
as	NULL
high	NULL
as	NULL
1	NULL
ug/ml	NULL
were	NULL
not	NULL
effective	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
confirm	NULL
the	NULL
in	NULL
vitro	NULL
data	NULL
for	NULL
inhibition	NULL
of	NULL
AP-1	NULL
by	NULL
Dex	NULL
and	NULL
suggest	NULL
that	NULL
this	NULL
inhibition	NULL
does	NULL
not	NULL
require	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
motifs	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

The	NULL
discrepancy	NULL
between	NULL
the	NULL
in	NULL
vitro	NULL
and	NULL
the	NULL
in	NULL
vivo	NULL
data	NULL
observed	NULL
when	NULL
CsA	NULL
was	NULL
used	NULL
may	NULL
be	NULL
due	NULL
to	NULL
the	NULL
difference	NULL
in	NULL
cell	NULL
types	NULL
(	NULL
primary	NULL
vs.	NULL
transformed	NULL
)	NULL
.	NULL

These	NULL
data	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
previous	NULL
reports	NULL
suggesting	NULL
that	NULL
in	NULL
Jurkat	NULL
cells	NULL
AP-1	NULL
activity	NULL
by	NULL
EMSA	NULL
or	NULL
transfection	NULL
assays	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
CsA	NULL
(	NULL
14	NULL
,	NULL
15	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
AP-1	NULL
activity	NULL
in	NULL
vitro	NULL
by	NULL
CsA	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
(	NULL
by	NULL
EMSA	NULL
)	NULL
has	NULL
also	NULL
been	NULL
reported	NULL
by	NULL
Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
.	NULL

NF-AT	NULL
activity	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
is	NULL
inhibited	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
nuclear	NULL
factor	NULL
AP-1	NULL
,	NULL
which	NULL
is	NULL
ubiquitous	NULL
,	NULL
NF-AT	NULL
has	NULL
been	NULL
found	NULL
only	NULL
in	NULL
lymphoid	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Unstimulated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
contain	NULL
no	NULL
detectable	NULL
activity	NULL
for	NULL
NF-AT	NULL
as	NULL
determined	NULL
by	NULL
EMSA	NULL
.	NULL

In	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
NF-AT	NULL
activity	NULL
appears	NULL
within	NULL
6	NULL
h	NULL
after	NULL
stimulation	NULL
and	NULL
continues	NULL
to	NULL
increase	NULL
until	NULL
it	NULL
reaches	NULL
a	NULL
peak	NULL
within	NULL
~	NULL
36	NULL
h	NULL
(	NULL
21	NULL
)	NULL
.	NULL

Induction	NULL
of	NULL
NF-AT	NULL
in	NULL
transformed	NULL
human	NULL
T	NULL
lymphocytes	NULL
requires	NULL
two	NULL
activation-dependent	NULL
effects	NULL
:	NULL
a	NULL
CsA-sensitive	NULL
translocation	NULL
of	NULL
a	NULL
preexisting	NULL
cytoplasmic	NULL
component	NULL
to	NULL
the	NULL
nucleus	NULL
and	NULL
a	NULL
CsA-resistant	NULL
synthesis	NULL
of	NULL
a	NULL
nuclear	NULL
component	NULL
(	NULL
35	NULL
)	NULL
.	NULL

Recent	NULL
data	NULL
in	NULL
murine	NULL
T	NULL
lymphocytes	NULL
suggest	NULL
that	NULL
the	NULL
CsA-insensitive	NULL
nuclear	NULL
component	NULL
is	NULL
AP-1	NULL
(	NULL
which	NULL
is	NULL
added	NULL
to	NULL
the	NULL
preexisting	NULL
NF-AT	NULL
complex	NULL
)	NULL
and	NULL
that	NULL
there	NULL
is	NULL
close	NULL
physical	NULL
and	NULL
functional	NULL
interaction	NULL
(	NULL
crosstalk	NULL
)	NULL
between	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
(	NULL
36	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
Dex	NULL
on	NULL
NF-AT	NULL
activity	NULL
.	NULL

Primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
were	NULL
stimulated	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
were	NULL
isolated	NULL
18	NULL
and	NULL
36	NULL
h	NULL
later	NULL
and	NULL
analyzed	NULL
by	NULL
EMSA	NULL
using	NULL
a	NULL
radiolabeled	NULL
oligonucleotide	NULL
probe	NULL
for	NULL
the	NULL
AT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
.	NULL

Unstimulated	NULL
cells	NULL
did	NULL
not	NULL
exhibit	NULL
any	NULL
AT	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
resulted	NULL
in	NULL
induction	NULL
of	NULL
AT	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
inhibited	NULL
by	NULL
both	NULL
Dex	NULL
or	NULL
CsA	NULL
at	NULL
36	NULL
h	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Analysis	NULL
at	NULL
8	NULL
and	NULL
18	NULL
h	NULL
revealed	NULL
similar	NULL
results	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
was	NULL
sequence	NULL
specific	NULL
,	NULL
as	NULL
demonstrated	NULL
by	NULL
competition	NULL
assays	NULL
with	NULL
related	NULL
and	NULL
unrelated	NULL
(	NULL
NF-kB	NULL
)	NULL
DNA	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
)	NULL
.	NULL

Inhibition	NULL
of	NULL
NF-AT	NULL
activity	NULL
by	NULL
CsA	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
corroborates	NULL
previous	NULL
findings	NULL
in	NULL
both	NULL
primary	NULL
and	NULL
transformed	NULL
T	NULL
lymphocytes	NULL
(	NULL
14-16	NULL
)	NULL
.	NULL

CsA	NULL
but	NULL
not	NULL
Dex	NULL
inhibits	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
a	NULL
transfected	NULL
plasmid	NULL
containing	NULL
the	NULL
AT	NULL
site	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

NF-AT	NULL
activity	NULL
is	NULL
inhibited	NULL
by	NULL
Dex	NULL
in	NULL
vitro	NULL
.	NULL

We	NULL
examined	NULL
these	NULL
phenomena	NULL
in	NULL
vivo	NULL
by	NULL
transfection	NULL
assays	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
pNF-AT	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NF-AT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Plasmids	NULL
containing	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
NF-AT	NULL
site	NULL
are	NULL
not	NULL
inducible	NULL
(	NULL
5	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
unstimulated	NULL
Jurkat	NULL
cells	NULL
did	NULL
not	NULL
exhibit	NULL
any	NULL
detectable	NULL
CAT	NULL
activity	NULL
.	NULL

Neither	NULL
Dex	NULL
nor	NULL
CsA	NULL
affected	NULL
the	NULL
baseline	NULL
activity	NULL
of	NULL
this	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
Jurkat	NULL
cells	NULL
led	NULL
to	NULL
a	NULL
dramatic	NULL
induction	NULL
of	NULL
pNF-AT	NULL
CAT	NULL
.	NULL

Dex	NULL
at	NULL
10~°	NULL
or	NULL
10~	NULL
'	NULL
M	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
plasmid	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Harvesting	NULL
of	NULL
F.	NULL
Paliogianni	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.	NULL
S.	NULL
Ahuja	NULL
,	NULL
S.	NULL
M.	NULL
Najjar	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
AP-1	NULL
CAT	NULL
AL	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
-	NULL
+	NULL
+	NULL
+	NULL
_	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
_-Dex	NULL
.	NULL

10-65M	NULL
-	NULL
+	NULL
-	NULL
+	NULL
-	NULL
CsA	NULL
Dex	NULL
.	NULL

10-	NULL
``	NULL
M	NULL
_	NULL
-	NULL
-	NULL
-	NULL
-	NULL
+	NULL
cells	NULL
at	NULL
various	NULL
time	NULL
points	NULL
(	NULL
8	NULL
,	NULL
16	NULL
,	NULL
or	NULL
36	NULL
h	NULL
)	NULL
also	NULL
did	NULL
-not	NULL
affect	NULL
the	NULL
results	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
Dex	NULL
,	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
completely	NULL
inhibited	NULL
the	NULL
activity	NULL
of	NULL
pNF-AT	NULL
CAT	NULL
.	NULL

Doses	NULL
of	NULL
CsA	NULL
as	NULL
low	NULL
as	NULL
1	NULL
ng/ml	NULL
inhibited	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
plasmid	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
CsA	NULL
is	NULL
a	NULL
potent	NULL
inhibitor	NULL
of	NULL
NF-AT	NULL
activity	NULL
and	NULL
that	NULL
its	NULL
inhibitory	NULL
effect	NULL
does	NULL
not	NULL
require	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Lack	NULL
of	NULL
inhibition	NULL
of	NULL
pNF-AT	NULL
activity	NULL
in	NULL
vivo	NULL
by	NULL
Dex	NULL
in	NULL
Jurkat	NULL
cells	NULL
could	NULL
be	NULL
due	NULL
to	NULL
(	NULL
a	NULL
)	NULL
resistance	NULL
of	NULL
transformed	NULL
T	NULL
lymphocytes	NULL
(	NULL
compared	NULL
with	NULL
primary	NULL
T	NULL
lymphocytes	NULL
)	NULL
;	NULL
(	NULL
b	NULL
)	NULL
the	NULL
presence	NULL
of	NULL
three	NULL
NF-AT	NULL
sites	NULL
in	NULL
the	NULL
plasmid	NULL
used	NULL
for	NULL
these	NULL
Figure	NULL
5	NULL
.	NULL

NF-AT	NULL
activity	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
is	NULL
inhibited	NULL
by	NULL
DEX	NULL
or	NULL
CsA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
resting	NULL
or	NULL
stimulated	NULL
T	NULL
lymphocytes	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
P-end-la-beled	NULL
30	NULL
bp	NULL
DNA	NULL
probe	NULL
that	NULL
included	NULL
the	NULL
NF-AT	NULL
binding	NULL
domain	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
was	NULL
used	NULL
in	NULL
this	NULL
assay	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
four	NULL
different	NULL
experiments	NULL
.	NULL

NF-AT	NULL
Figure	NULL
4	NULL
.	NULL

Dex	NULL
but	NULL
not	NULL
CsA	NULL
inhibits	NULL
the	NULL
activity	NULL
of	NULL
an	NULL
AP-1	NULL
reporter	NULL
construct	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
AP-1	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
collagenase	NULL
gene	NULL
cloned	NULL
in	NULL
pBLCAT2	NULL
(	NULL
23	NULL
)	NULL
.	NULL

After	NULL
transfection	NULL
,	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Dex	NULL
(	NULL
10	NULL
~	NULL
or	NULL
10~	NULL
'	NULL
M	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
(	NULL
separate	NULL
experiment	NULL
)	NULL
for	NULL
18	NULL
h	NULL
and	NULL
analyzed	NULL
for	NULL
CAT	NULL
activity	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
independent	NULL
experiments	NULL
.	NULL

Dex	NULL
inhibited	NULL
the	NULL
CAT	NULL
#	NULL
#	NULL
f	NULL
activity	NULL
in	NULL
this	NULL
experiment	NULL
by	NULL
~	NULL
70	NULL
~	NULL
+	NULL
+	NULL
(	NULL
10~°	NULL
M	NULL
)	NULL
and	NULL
~	NULL
30	NULL
%	NULL
(	NULL
10~	NULL
``	NULL
M	NULL
)	NULL
.	NULL

+	NULL
-	NULL
+	NULL
No	NULL
inhibition	NULL
was	NULL
observed	NULL
with	NULL
CsA	NULL
.	NULL

experiments	NULL
instead	NULL
of	NULL
a	NULL
single	NULL
site	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
;	NULL
or	NULL
(	NULL
c	NULL
)	NULL
to	NULL
Dex	NULL
requiring	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
sites	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
order	NULL
that	NULL
it	NULL
may	NULL
inhibit	NULL
NF-AT	NULL
activity	NULL
.	NULL

Analysis	NULL
of	NULL
Jurkat	NULL
cells	NULL
by	NULL
EMSA	NULL
demonstrated	NULL
that	NULL
both	NULL
Dex	NULL
(	NULL
10°	NULL
M	NULL
)	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
human	NULL
NF-AT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
(	NULL
Fig	NULL
.	NULL

7	NULL
)	NULL
.	NULL

When	NULL
higher	NULL
concentrations	NULL
of	NULL
Dex	NULL
were	NULL
used	NULL
(	NULL
10~°	NULL
M	NULL
)	NULL
in	NULL
DNA	NULL
transfection	NULL
assays	NULL
with	NULL
pNF-AT	NULL
,	NULL
CAT	NULL
results	NULL
were	NULL
identical	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
NF-AT	NULL
site	NULL
,	NULL
by	NULL
itself	NULL
,	NULL
is	NULL
not	NULL
sufficient	NULL
for	NULL
GC	NULL
mediated	NULL
inhibition	NULL
.	NULL

Given	NULL
the	NULL
highly	NULL
cooperative	NULL
interaction	NULL
among	NULL
the	NULL
various	NULL
transcription	NULL
factors	NULL
for	NULL
the	NULL
IL-2	NULL
gene	NULL
promoter	NULL
(	NULL
27	NULL
)	NULL
,	NULL
it	NULL
is	NULL
possible	NULL
that	NULL
additional	NULL
sites	NULL
are	NULL
required	NULL
in	NULL
order	NULL
that	NULL
NF-AT	NULL
may	NULL
confer	NULL
susceptibility	NULL
to	NULL
GC	NULL
(	NULL
see	NULL
Discussion	NULL
)	NULL
.	NULL

Neither	NULL
Dex	NULL
nor	NULL
CsA	NULL
inhibits	NULL
the	NULL
activity	NULL
of	NULL
nuclear	NULL
proteins	NULL
binding	NULL
to	NULL
the	NULL
OCT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
.	NULL

OCT	NULL
-1	NULL
is	NULL
a	NULL
ubiquitous	NULL
octamer	NULL
binding	NULL
nuclear	NULL
protein	NULL
that	NULL
participates	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
interacting	NULL
with	NULL
both	NULL
DNA	NULL
and	NULL
a	NULL
40-kD	NULL
protein	NULL
called	NULL
-associated	NULL
protein	NULL
(	NULL
OAP	NULL
)	NULL
(	NULL
37	NULL
)	NULL
.	NULL

Two	NULL
octamer-binding	NULL
sites	NULL
are	NULL
identified	NULL
in	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
,	NULL
one	NULL
proximal	NULL
and	NULL
one	NULL
distal	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

Protein	NULL
extracts	NULL
of	NULL
stimulated	NULL
primary	NULL
T	NULL
lymphocytes	NULL
bind	NULL
very	NULL
poorly	NULL
to	NULL
the	NULL
OCT	NULL
-1	NULL
distal	NULL
site	NULL
(	NULL
21	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
binding	NULL
to	NULL
the	NULL
proximal	NULL
OCT	NULL
is	NULL
strong	NULL
.	NULL

Levels	NULL
of	NULL
OCT	NULL
-1	NULL
activity	NULL
are	NULL
low	NULL
in	NULL
unstimulated	NULL
T	NULL
cells	NULL
and	NULL
are	NULL
induced	NULL
after	NULL
stimulation	NULL
reaching	NULL
a	NULL
peak	NULL
at	NULL
~	NULL
6	NULL
h	NULL
(	NULL
21	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8	NULL
,	NULL
unstimulated	NULL
primary	NULL
T	NULL
lymphocytes	NULL
exhibited	NULL
low	NULL
levels	NULL
of	NULL
OCT	NULL
-1	NULL
binding	NULL
activity	NULL
that	NULL
were	NULL
not	NULL
affected	NULL
by	NULL
pretreatment	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Two	NULL
bands	NULL
are	NULL
apparent	NULL
in	NULL
this	NULL
figure	NULL
,	NULL
one	NULL
upper	NULL
and	NULL
one	NULL
lower	NULL
.	NULL

Competition	NULL
with	NULL
related	NULL
cold	NULL
oligonucleotide	NULL
(	NULL
OCT	NULL
-1	NULL
)	NULL
completely	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
the	NULL
label	NULL
in	NULL
the	NULL
upper	NULL
band	NULL
,	NULL
whereas	NULL
it	NULL
competed	NULL
less	NULL
effectively	NULL
for	NULL
binding	NULL
in	NULL
the	NULL
lower	NULL
band	NULL
.	NULL

Competition	NULL
with	NULL
a	NULL
heterologous	NULL
(	NULL
NF-kB	NULL
)	NULL
oligonucleotide	NULL
did	NULL
not	NULL
exhibit	NULL
any	NULL
demonstrable	NULL
effect	NULL
on	NULL
binding	NULL
of	NULL
these	NULL
proteins	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
upper	NULL
band	NULL
is	NULL
specific	NULL
for	NULL
OCT-1	NULL
,	NULL
whereas	NULL
binding	NULL
to	NULL
the	NULL
lower	NULL
band	NULL
represents	NULL
nonspecific	NULL
binding	NULL
.	NULL

Both	NULL
Dex	NULL
or	NULL
CsA	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
OCT-1/OAP	NULL
nuclear	NULL
proteins	NULL
.	NULL

NF-kB	NULL
activity	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

NF-kB	NULL
is	NULL
involved	NULL
in	NULL
the	NULL
inducible	NULL
transcription	NULL
of	NULL
several	NULL
genes	NULL
coding	NULL
for	NULL
cytokines	NULL
or	NULL
their	NULL
receptors	NULL
(	NULL
27	NULL
,	NULL
38-41	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
IL-	NULL
Mechanism	NULL
of	NULL
Immunosuppression	NULL
by	NULL
Glucocorticoids	NULL
1485	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
_	NULL
Dex	NULL
.	NULL

10-5M	NULL
Dex	NULL
.	NULL

10-	NULL
'M	NULL
_	NULL
NF-AT	NULL
CAT	NULL
+	NULL
+	NULL
+	NULL
--	NULL
+	NULL
lon	NULL
.	NULL

+	NULL
PMA	NULL
_	NULL
=	NULL
~-CsA	NULL
-	NULL
+	NULL
Figure	NULL
6	NULL
.	NULL

CsA	NULL
but	NULL
not	NULL
Dex	NULL
inhibits	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
transfected	NULL
plasmid	NULL
containing	NULL
the	NULL
NF-AT	NULL
site	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
transiently	NULL
transfected	NULL
with	NULL
plasmid	NULL
NF-AT	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
AT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
linked	NULL
to	NULL
the	NULL
CAT	NULL
gene	NULL
,	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Cells	NULL
were	NULL
exposed	NULL
to	NULL
Dex	NULL
or	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
before	NULL
stimulation	NULL
.	NULL

After	NULL
stimulation	NULL
for	NULL
16	NULL
h	NULL
,	NULL
cells	NULL
were	NULL
analyzed	NULL
for	NULL
CAT	NULL
activity	NULL
.	NULL

Densitometric	NULL
analysis	NULL
revealed	NULL
no	NULL
inhibition	NULL
for	NULL
Dex	NULL
and	NULL
100	NULL
%	NULL
inhibition	NULL
for	NULL
CsA	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
different	NULL
experiments	NULL
.	NULL

\	NULL
2Ra	NULL
gene	NULL
,	NULL
where	NULL
NF-kB	NULL
is	NULL
essential	NULL
for	NULL
transcription	NULL
,	NULL
its	NULL
relative	NULL
importance	NULL
for	NULL
IL-2	NULL
promoter	NULL
activity	NULL
is	NULL
not	NULL
well	NULL
established	NULL
(	NULL
5	NULL
,	NULL
7	NULL
,	NULL
27	NULL
)	NULL
.	NULL

In	NULL
unstimulated	NULL
human	NULL
T	NULL
lymphocytes	NULL
low	NULL
to	NULL
undetectable	NULL
levels	NULL
of	NULL
NF-kB	NULL
activity	NULL
are	NULL
present	NULL
by	NULL
EMSA	NULL
.	NULL

Stimulation	NULL
of	NULL
T	NULL
lymphocytes	NULL
leads	NULL
to	NULL
a	NULL
rapid	NULL
induction	NULL
of	NULL
NF-kB	NULL
activity	NULL
,	NULL
which	NULL
peaks	NULL
within	NULL
6	NULL
h	NULL
and	NULL
persists	NULL
at	NULL
similar	NULL
levels	NULL
for	NULL
>	NULL
36	NULL
hours	NULL
(	NULL
21	NULL
)	NULL
.	NULL

As	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

9	NULL
,	NULL
unstimulated	NULL
T	NULL
lymphocytes	NULL
expressed	NULL
low	NULL
levels	NULL
of	NULL
activity	NULL
for	NULL
the	NULL
kB	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
by	NULL
EMSA	NULL
.	NULL

Dex	NULL
increased	NULL
approximately	NULL
1486	NULL
NF-AT	NULL
Figure	NULL
7	NULL
.	NULL

Both	NULL
Dex	NULL
and	NULL
CsA	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
the	NULL
NF-AT	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
Dex	NULL
(	NULL
107°	NULL
or	NULL
107	NULL
``	NULL
M	NULL
)	NULL
or	NULL
CsA	NULL
(	NULL
100	NULL
ng/ml	NULL
)	NULL
and	NULL
analyzed	NULL
by	NULL
EMSA	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
different	NULL
experiments	NULL
.	NULL

twofold	NULL
the	NULL
baseline	NULL
NF-kB	NULL
activity	NULL
(	NULL
Fig	NULL
.	NULL

9	NULL
)	NULL
but	NULL
not	NULL
CsA	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Stimulation	NULL
with	NULL
ionomycin	NULL
and	NULL
PMA	NULL
led	NULL
to	NULL
a	NULL
marked	NULL
induction	NULL
of	NULL
NF-kB	NULL
activity	NULL
,	NULL
which	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

Specificity	NULL
of	NULL
binding	NULL
was	NULL
again	NULL
confirmed	NULL
by	NULL
OCT-1	NULL
F.	NULL
Paliogianni	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.	NULL
S.	NULL
Ahuja	NULL
,	NULL
S.	NULL
M.	NULL
Najjar	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
Figure	NULL
8	NULL
.	NULL

Binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
from	NULL
stimulated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
to	NULL
the	NULL
OCT-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
Dex	NULL
or	NULL
CsA	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
were	NULL
prepared	NULL
and	NULL
analyzed	NULL
as	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
P-end-la-beled	NULL
DNA	NULL
probe	NULL
(	NULL
16	NULL
bp	NULL
)	NULL
that	NULL
includes	NULL
the	NULL
DNA	NULL
binding	NULL
domain	NULL
of	NULL
OCT-1/OAF	NULL
was	NULL
used	NULL
in	NULL
this	NULL
experiment	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
three	NULL
different	NULL
experiments	NULL
.	NULL

Figure	NULL
9	NULL
.	NULL

Neither	NULL
Dex	NULL
nor	NULL
CsA	NULL
inhibits	NULL
the	NULL
binding	NULL
of	NULL
nuclear	NULL
proteins	NULL
to	NULL
kB	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Nuclear	NULL
extracts	NULL
from	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
were	NULL
analyzed	NULL
by	NULL
EMSA	NULL
as	NULL
described	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

A	NULL
DNA	NULL
probe	NULL
(	NULL
-206	NULL
to	NULL
-195	NULL
to	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
)	NULL
that	NULL
includes	NULL
to	NULL
the	NULL
DNA	NULL
binding	NULL
site	NULL
of	NULL
NF-kB	NULL
on	NULL
the	NULL
IL-2	NULL
promoter	NULL
was	NULL
used	NULL
.	NULL

Results	NULL
are	NULL
representative	NULL
of	NULL
two	NULL
different	NULL
experiments	NULL
.	NULL

NF-xB	NULL
competition	NULL
assays	NULL
with	NULL
cold	NULL
related	NULL
(	NULL
NF-kB	NULL
)	NULL
and	NULL
unrelated	NULL
(	NULL
AP-1	NULL
)	NULL
oligonucleotide	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

We	NULL
next	NULL
determined	NULL
whether	NULL
Dex	NULL
or	NULL
CsA	NULL
will	NULL
inhibit	NULL
NF-kB	NULL
activity	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Plasmid	NULL
NF-kB	NULL
CAT	NULL
,	NULL
which	NULL
contains	NULL
a	NULL
single	NULL
copy	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
kB	NULL
site	NULL
,	NULL
was	NULL
transfected	NULL
into	NULL
Jurkat	NULL
cells	NULL
.	NULL

Neither	NULL
Dex	NULL
or	NULL
CsA	NULL
inhibited	NULL
the	NULL
induction	NULL
of	NULL
NF-kB	NULL
activity	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
NF-kB	NULL
is	NULL
not	NULL
likely	NULL
to	NULL
mediate	NULL
inhibition	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
by	NULL
Dex	NULL
.	NULL

Lack	NULL
of	NULL
inhibition	NULL
of	NULL
NF-kB	NULL
activity	NULL
by	NULL
CsA	NULL
has	NULL
been	NULL
reported	NULL
also	NULL
by	NULL
Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
,	NULL
whereas	NULL
other	NULL
groups	NULL
have	NULL
reported	NULL
partial	NULL
inhibition	NULL
(	NULL
14	NULL
,	NULL
17	NULL
)	NULL
.	NULL

Discussion	NULL
We	NULL
have	NULL
presented	NULL
a	NULL
series	NULL
of	NULL
studies	NULL
aimed	NULL
at	NULL
defining	NULL
the	NULL
mechanism	NULL
(	NULL
s	NULL
)	NULL
of	NULL
GC-mediated	NULL
inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
nuclear	NULL
transcription	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

To	NULL
better	NULL
understand	NULL
this	NULL
inhibition	NULL
and	NULL
put	NULL
the	NULL
effect	NULL
of	NULL
GC	NULL
in	NULL
perspective	NULL
,	NULL
we	NULL
have	NULL
also	NULL
studied	NULL
transformed	NULL
human	NULL
T	NULL
lymphocytes	NULL
(	NULL
Jur-kat	NULL
cells	NULL
)	NULL
and	NULL
have	NULL
compared	NULL
the	NULL
effects	NULL
of	NULL
GC	NULL
with	NULL
those	NULL
of	NULL
CsA	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
GC	NULL
,	NULL
both	NULL
in	NULL
primary	NULL
and	NULL
transformed	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
is	NULL
mediated	NULL
by	NULL
interference	NULL
with	NULL
nuclear	NULL
factors	NULL
AP-1	NULL
and	NULL
AT	NULL
.	NULL

Furthermore	NULL
,	NULL
our	NULL
data	NULL
suggest	NULL
that	NULL
while	NULL
maximum	NULL
inhibition	NULL
of	NULL
IL-2	NULL
promoter	NULL
transcription	NULL
may	NULL
involve	NULL
interaction	NULL
with	NULL
both	NULL
transcription	NULL
factors	NULL
,	NULL
AP-1	NULL
seems	NULL
to	NULL
be	NULL
the	NULL
primary	NULL
target	NULL
of	NULL
GC	NULL
because	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
NF-AT	NULL
,	NULL
its	NULL
inhibition	NULL
does	NULL
not	NULL
require	NULL
the	NULL
presence	NULL
of	NULL
other	NULL
motifs	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

Fi-nally	NULL
,	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
CsA	NULL
in	NULL
primary	NULL
T	NULL
lymphocytes	NULL
involves	NULL
interference	NULL
with	NULL
both	NULL
NF-AT	NULL
and	NULL
AP-1	NULL
,	NULL
whereas	NULL
in	NULL
Jurkat	NULL
cells	NULL
inhibition	NULL
is	NULL
mediated	NULL
mainly	NULL
through	NULL
NF-AT	NULL
.	NULL

Our	NULL
results	NULL
are	NULL
reminiscent	NULL
of	NULL
findings	NULL
recently	NULL
reported	NULL
by	NULL
Vacca	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
.	NULL

By	NULL
mutational	NULL
analysis	NULL
of	NULL
human	NULL
IL-2	NULL
promoter	NULL
in	NULL
a	NULL
system	NULL
using	NULL
transfection	NULL
in	NULL
Jurkat	NULL
cells	NULL
,	NULL
these	NULL
investigators	NULL
found	NULL
that	NULL
mutants	NULL
carrying	NULL
deletions	NULL
disrupting	NULL
the	NULL
NF-AT	NULL
and	NULL
the	NULL
proximal	NULL
AP-1i	NULL
-like	NULL
motif	NULL
impaired	NULL
their	NULL
ability	NULL
to	NULL
be	NULL
inhibited	NULL
by	NULL
GC	NULL
.	NULL

A	NULL
homooligomer	NULL
of	NULL
NF-AT	NULL
was	NULL
found	NULL
to	NULL
be	NULL
inducible	NULL
by	NULL
ionomycin	NULL
and	NULL
PMA	NULL
.	NULL

Dex	NULL
did	NULL
not	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
construct	NULL
.	NULL

When	NULL
an	NULL
AP-1	NULL
motif	NULL
con-catemer	NULL
was	NULL
used	NULL
,	NULL
calcium	NULL
ionophores	NULL
and	NULL
PMA	NULL
failed	NULL
to	NULL
induce	NULL
it	NULL
significantly	NULL
.	NULL

Based	NULL
on	NULL
these	NULL
results	NULL
,	NULL
they	NULL
concluded	NULL
that	NULL
the	NULL
AP-1	NULL
motif	NULL
confers	NULL
GC	NULL
sensitivity	NULL
to	NULL
a	NULL
flanking	NULL
region	NULL
containing	NULL
an	NULL
NF-AT	NULL
element	NULL
and	NULL
suggested	NULL
that	NULL
,	NULL
in	NULL
order	NULL
that	NULL
GC	NULL
may	NULL
inhibit	NULL
IL-2	NULL
gene	NULL
transcription	NULL
,	NULL
a	NULL
synergistic	NULL
cooperativity	NULL
is	NULL
required	NULL
between	NULL
the	NULL
NF-AT	NULL
and	NULL
the	NULL
AP-1	NULL
sites	NULL
.	NULL

The	NULL
experiments	NULL
presented	NULL
herein	NULL
,	NULL
while	NULL
not	NULL
necessarily	NULL
excluding	NULL
cooperation	NULL
between	NULL
AP-1	NULL
and	NULL
NF-AT	NULL
in	NULL
mediating	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
Dex	NULL
,	NULL
also	NULL
suggest	NULL
that	NULL
the	NULL
AP-1	NULL
motif	NULL
(	NULL
but	NULL
not	NULL
the	NULL
NF-AT	NULL
)	NULL
of	NULL
IL-2	NULL
promoter	NULL
may	NULL
be	NULL
sufficient	NULL
for	NULL
inhibition	NULL
by	NULL
Dex	NULL
.	NULL

Inability	NULL
to	NULL
demonstrate	NULL
inhibition	NULL
of	NULL
the	NULL
AP-1	NULL
noncatemer	NULL
used	NULL
by	NULL
Vacca	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
by	NULL
Dex	NULL
is	NULL
due	NULL
to	NULL
its	NULL
failure	NULL
to	NULL
be	NULL
induced	NULL
after	NULL
stimulation	NULL
.	NULL

A	NULL
multimerized	NULL
AP-1	NULL
construct	NULL
derived	NULL
from	NULL
the	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
AP-CAT/NFIL2B2H	NULL
)	NULL
,	NULL
when	NULL
used	NULL
by	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
,	NULL
was	NULL
inducible	NULL
after	NULL
stimulation	NULL
.	NULL

Dex	NULL
inhibited	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
construct	NULL
by	NULL
78	NULL
%	NULL
(	NULL
compared	NULL
with	NULL
100	NULL
%	NULL
inhibition	NULL
of	NULL
the	NULL
intact	NULL
IL-2	NULL
promoter	NULL
)	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
results	NULL
raise	NULL
the	NULL
intriguing	NULL
possibility	NULL
that	NULL
,	NULL
similar	NULL
to	NULL
activation	NULL
of	NULL
IL-2	NULL
promoter	NULL
,	NULL
where	NULL
multiple	NULL
transcriptional	NULL
factors	NULL
are	NULL
required	NULL
for	NULL
optimal	NULL
activity	NULL
,	NULL
maximal	NULL
repression	NULL
by	NULL
GC	NULL
may	NULL
involve	NULL
interaction	NULL
with	NULL
more	NULL
than	NULL
a	NULL
single	NULL
factor	NULL
and/or	NULL
binding	NULL
site	NULL
.	NULL

Recent	NULL
work	NULL
in	NULL
murine	NULL
cells	NULL
has	NULL
suggested	NULL
that	NULL
AP-1	NULL
is	NULL
important	NULL
for	NULL
binding	NULL
and	NULL
activity	NULL
of	NULL
NF-AT	NULL
and	NULL
has	NULL
also	NULL
suggested	NULL
a	NULL
close	NULL
physical	NULL
and	NULL
functional	NULL
interaction	NULL
between	NULL
these	NULL
two	NULL
factors	NULL
(	NULL
36	NULL
)	NULL
.	NULL

Our	NULL
work	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
the	NULL
primary	NULL
target	NULL
of	NULL
GC	NULL
in	NULL
mediating	NULL
inhibition	NULL
of	NULL
IL-2	NULL
promoter	NULL
activity	NULL
is	NULL
transcriptional	NULL
factor	NULL
AP-1	NULL
,	NULL
whereas	NULL
its	NULL
effect	NULL
on	NULL
NF-AT	NULL
activity	NULL
may	NULL
be	NULL
,	NULL
at	NULL
least	NULL
in	NULL
part	NULL
,	NULL
indirect	NULL
,	NULL
through	NULL
decreasing	NULL
AP-1	NULL
activity	NULL
.	NULL

A	NULL
functional	NULL
antagonism	NULL
that	NULL
involves	NULL
direct	NULL
protein	NULL
to	NULL
protein	NULL
interactions	NULL
between	NULL
AP-1	NULL
and	NULL
GR	NULL
has	NULL
been	NULL
reported	NULL
by	NULL
several	NULL
investigators	NULL
(	NULL
28-30	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
the	NULL
proximal	NULL
AP-1	NULL
site	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
binds	NULL
an	NULL
inducible	NULL
protein	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
a	NULL
protein	NULL
that	NULL
contains	NULL
both	NULL
c-jun	NULL
and	NULL
c-	NULL
fos	NULL
proteins	NULL
and	NULL
mediates	NULL
repression	NULL
by	NULL
GC	NULL
.	NULL

Vacca	NULL
et	NULL
al	NULL
.	NULL

(	NULL
11	NULL
)	NULL
have	NULL
also	NULL
shown	NULL
that	NULL
the	NULL
proximal	NULL
AP-1	NULL
motif	NULL
of	NULL
the	NULL
human	NULL
IL-2	NULL
promoter	NULL
binds	NULL
an	NULL
inducible	NULL
complex	NULL
containing	NULL
c-	NULL
fos	NULL
protein	NULL
in	NULL
Jurkat	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
differ	NULL
from	NULL
those	NULL
recently	NULL
reported	NULL
by	NULL
Northrop	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
,	NULL
who	NULL
suggest	NULL
that	NULL
inhibition	NULL
of	NULL
IL-2	NULL
transcription	NULL
by	NULL
GC	NULL
is	NULL
mediated	NULL
by	NULL
direct	NULL
interaction	NULL
between	NULL
GR	NULL
and	NULL
a	NULL
factor	NULL
that	NULL
binds	NULL
to	NULL
two	NULL
sequences	NULL
located	NULL
in	NULL
the	NULL
proximal	NULL
half	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
(	NULL
NKIL2B/AP-1	NULL
and	NULL
NFIL2A/OCT-1/OAP	NULL
)	NULL
.	NULL

These	NULL
sequences	NULL
bind	NULL
a	NULL
similar	NULL
,	NULL
if	NULL
not	NULL
identical	NULL
,	NULL
inducible	NULL
nuclear	NULL
factor	NULL
that	NULL
has	NULL
biological	NULL
characteristics	NULL
that	NULL
distinguish	NULL
it	NULL
from	NULL
AP-1	NULL
(	NULL
likely	NULL
OAP	NULL
)	NULL
(	NULL
12	NULL
)	NULL
.	NULL

The	NULL
discrepancy	NULL
of	NULL
these	NULL
results	NULL
may	NULL
be	NULL
due	NULL
to	NULL
differences	NULL
in	NULL
cell	NULL
types	NULL
used	NULL
(	NULL
primary	NULL
or	NULL
transformed	NULL
human	NULL
vs.	NULL
transformed	NULL
human	NULL
or	NULL
murine	NULL
)	NULL
or	NULL
to	NULL
differences	NULL
in	NULL
experimental	NULL
protocols	NULL
.	NULL

To	NULL
our	NULL
knowledge	NULL
this	NULL
is	NULL
the	NULL
first	NULL
demonstration	NULL
of	NULL
GC	NULL
inhibiting	NULL
IL-2	NULL
transcription	NULL
by	NULL
interfering	NULL
with	NULL
nuclear	NULL
factors	NULL
Mechanism	NULL
of	NULL
Immunosuppression	NULL
by	NULL
Glucocorticoids	NULL
__	NULL
1487	NULL
for	NULL
IL-2	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
have	NULL
also	NULL
studied	NULL
the	NULL
effects	NULL
of	NULL
GC	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
nuclear	NULL
factors	NULL
binding	NULL
in	NULL
the	NULL
IL-2	NULL
promoter	NULL
in	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
.	NULL

Dex	NULL
at	NULL
10	NULL
~	NULL
'	NULL
M	NULL
,	NULL
while	NULL
blocking	NULL
the	NULL
increase	NULL
in	NULL
IL-2	NULL
mRNA	NULL
in	NULL
stimulated	NULL
primary	NULL
human	NULL
T	NULL
lymphocytes	NULL
,	NULL
did	NULL
not	NULL
inhibit	NULL
binding	NULL
of	NULL
nuclear	NULL
factors	NULL
AP-1	NULL
,	NULL
AP-3	NULL
,	NULL
NF-kB	NULL
,	NULL
OCT-1	NULL
,	NULL
and	NULL
NF-AT	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
relatively	NULL
high	NULL
doses	NULL
of	NULL
Dex	NULL
are	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
IL-2	NULL
gene	NULL
transcription	NULL
as	NULL
determined	NULL
by	NULL
nuclear	NULL
run-off	NULL
assays	NULL
(	NULL
minimum	NULL
effective	NULL
dose	NULL
10~°	NULL
M	NULL
)	NULL
,	NULL
whereas	NULL
lower	NULL
concentrations	NULL
(	NULL
107°	NULL
M	NULL
)	NULL
are	NULL
required	NULL
for	NULL
inhibition	NULL
of	NULL
IL-2	NULL
mRNA	NULL
and	NULL
protein	NULL
product	NULL
.	NULL

This	NULL
discrepancy	NULL
is	NULL
due	NULL
to	NULL
posttranscriptional	NULL
effects	NULL
of	NULL
GC	NULL
on	NULL
IL-2	NULL
gene	NULL
expression	NULL
(	NULL
2	NULL
)	NULL
.	NULL

Thus	NULL
,	NULL
the	NULL
difference	NULL
between	NULL
our	NULL
results	NULL
and	NULL
those	NULL
reported	NULL
by	NULL
Granelli-Piperno	NULL
et	NULL
al	NULL
.	NULL

(	NULL
16	NULL
)	NULL
is	NULL
due	NULL
to	NULL
lower	NULL
doses	NULL
of	NULL
Dex	NULL
used	NULL
by	NULL
these	NULL
investigators	NULL
(	NULL
107°	NULL
M	NULL
vs.	NULL
107	NULL
``	NULL
M	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
GC	NULL
comparable	NULL
to	NULL
10~°	NULL
M	NULL
of	NULL
Dex	NULL
used	NULL
in	NULL
these	NULL
experiments	NULL
are	NULL
certainly	NULL
achievable	NULL
in	NULL
vivo	NULL
by	NULL
doses	NULL
of	NULL
prednisone	NULL
of	NULL
>	NULL
1	NULL
mg/kg	NULL
or	NULL
methyl-prednisolone	NULL
similar	NULL
to	NULL
those	NULL
used	NULL
for	NULL
pulse	NULL
therapy	NULL
(	NULL
>	NULL
15	NULL
mg/	NULL
kg	NULL
)	NULL
.	NULL

An	NULL
infusion	NULL
of	NULL
40	NULL
mg	NULL
of	NULL
cortisol	NULL
(	NULL
equivalent	NULL
to	NULL
10	NULL
mg	NULL
of	NULL
prednisone	NULL
or	NULL
1.3	NULL
mg	NULL
of	NULL
Dex	NULL
)	NULL
will	NULL
result	NULL
in	NULL
plasma	NULL
cortisol	NULL
levels	NULL
of	NULL
~	NULL
1-4	NULL
X	NULL
10~°	NULL
M	NULL
(	NULL
42	NULL
)	NULL
.	NULL

These	NULL
facts	NULL
are	NULL
important	NULL
to	NULL
bear	NULL
in	NULL
mind	NULL
when	NULL
using	NULL
data	NULL
obtained	NULL
in	NULL
vitro	NULL
to	NULL
interpret	NULL
the	NULL
immunosuppressive	NULL
effects	NULL
of	NULL
GC	NULL
in	NULL
vivo	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Dr.	NULL
J.	NULL
E.	NULL
Balow	NULL
for	NULL
many	NULL
useful	NULL
suggestions	NULL
and	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
Dr.	NULL
U.	NULL
Sicbenlist	NULL
for	NULL
the	NULL
generous	NULL
gifts	NULL
of	NULL
several	NULL
plasmids	NULL
,	NULL
for	NULL
many	NULL
helpful	NULL
discussions	NULL
,	NULL
and	NULL
for	NULL
critical	NULL
review	NULL
of	NULL
the	NULL
manuscript	NULL
;	NULL
Dr.	NULL
M.	NULL
Karin	NULL
for	NULL
his	NULL
generous	NULL
gift	NULL
of	NULL
the	NULL
AP-1	NULL
plasmid	NULL
and	NULL
his	NULL
encouragement	NULL
;	NULL
Dr.	NULL
G.	NULL
Crabtree	NULL
for	NULL
the	NULL
NF-AT	NULL
plasmid	NULL
;	NULL
Dr.	NULL
R.	NULL
Bravo	NULL
for	NULL
the	NULL
c-jun	NULL
antibody	NULL
;	NULL
Lisa	NULL
Miller	NULL
for	NULL
her	NULL
valuable	NULL
help	NULL
in	NULL
manuscript	NULL
preparation	NULL
;	NULL
and	NULL
the	NULL
NIH	NULL
Transfusion	NULL
Medicine	NULL
staff	NULL
for	NULL
their	NULL
help	NULL
with	NULL
leukapheresis	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
F.	NULL
Paliogianni	NULL
,	NULL
E.	NULL
D.	NULL
Anastassiou	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Balow	NULL
.	NULL

1991	NULL
.	NULL

Glucocorticosteroid	NULL
action	NULL
on	NULL
the	NULL
immune	NULL
system	NULL
:	NULL
molecular	NULL
and	NULL
cellular	NULL
aspects	NULL
.	NULL

Clin	NULL
.	NULL

Exp	NULL
.	NULL

Rheumatol	NULL
.	NULL

9:413-423	NULL
.	NULL

2	NULL
.	NULL

Boumpas	NULL
,	NULL
D.	NULL
T.	NULL
,	NULL
E.	NULL
D.	NULL
Anastassiou	NULL
,	NULL
S.	NULL
A	NULL
.	NULL

Older	NULL
,	NULL
G.	NULL
C.	NULL
Tsokos	NULL
,	NULL
D.	NULL
L.	NULL
Nelson	NULL
,	NULL
and	NULL
J.	NULL
E.	NULL
Balow	NULL
.	NULL

1991	NULL
.	NULL

Dexamethasone	NULL
inhibits	NULL
human	NULL
interleukin	NULL
2	NULL
but	NULL
not	NULL
interleukin	NULL
2	NULL
receptor	NULL
gene	NULL
expression	NULL
in	NULL
vitro	NULL
at	NULL
the	NULL
level	NULL
of	NULL
nuclear	NULL
transcription	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

$	NULL
7:1739-1747	NULL
.	NULL

3	NULL
.	NULL

Fujita	NULL
,	NULL
T.	NULL
,	NULL
H.	NULL
Shibuya	NULL
,	NULL
T.	NULL
Ohashi	NULL
,	NULL
K.	NULL
Kamanishi	NULL
,	NULL
and	NULL
T.	NULL
Taniguchi	NULL
.	NULL

1986	NULL
.	NULL

Regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
:	NULL
functional	NULL
DNA	NULL
sequences	NULL
in	NULL
the	NULL
5	NULL
flanking	NULL
region	NULL
for	NULL
the	NULL
gene	NULL
expression	NULL
in	NULL
activated	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cell	NULL
.	NULL

46:401-407	NULL
.	NULL

4	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
M.	NULL
R.	NULL
Rush	NULL
,	NULL
J.	NULL
G.	NULL
Morgans	NULL
,	NULL
A.	NULL
Weiss	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1987	NULL
.	NULL

A	NULL
275-base	NULL
pair	NULL
fragment	NULL
at	NULL
the	NULL
5	NULL
'	NULL
end	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
enhances	NULL
expression	NULL
from	NULL
a	NULL
heterologous	NULL
promoter	NULL
in	NULL
response	NULL
to	NULL
signals	NULL
from	NULL
the	NULL
T-cell	NULL
antigen	NULL
receptor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

165:395-407	NULL
.	NULL

5	NULL
.	NULL

Durand	NULL
,	NULL
D.	NULL
B.	NULL
,	NULL
J.	NULL
P.	NULL
Shaw	NULL
,	NULL
M.	NULL
R.	NULL
Bush	NULL
,	NULL
R.	NULL
E.	NULL
Replogle	NULL
,	NULL
R.	NULL
Belageje	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1988	NULL
.	NULL

Characterization	NULL
of	NULL
antigen	NULL
receptor	NULL
response	NULL
elements	NULL
within	NULL
the	NULL
interleukin	NULL
2	NULL
enhancer	NULL
.	NULL

Mo/	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

8:1715-1724	NULL
.	NULL

6	NULL
.	NULL

Brunvand	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
A.	NULL
Schmidt	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1988	NULL
.	NULL

Nuclear	NULL
factors	NULL
interacting	NULL
with	NULL
the	NULL
mitogen-responsive	NULL
regulatory	NULL
region	NULL
of	NULL
the	NULL
IL-2	NULL
gene	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

263:18904-18910	NULL
.	NULL

7	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
R.	NULL
Barthelmas	NULL
,	NULL
I.	NULL
Pfeuffer	NULL
,	NULL
B.	NULL
Schenk	NULL
,	NULL
S.	NULL
Zarius	NULL
,	NULL
R.	NULL
Swoboda	NULL
,	NULL
F.	NULL
Mercunio	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1989	NULL
.	NULL

Ubiquitous	NULL
and	NULL
lymphocyte-specific	NULL
factors	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
induction	NULL
of	NULL
the	NULL
mouse	NULL
interleukin	NULL
2	NULL
gene	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

$	NULL
:465-473	NULL
.	NULL

8	NULL
.	NULL

Fraser	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
Irving	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
A.	NULL
Weiss	NULL
.	NULL

1991	NULL
.	NULL

Regulation	NULL
of	NULL
interleukin-2	NULL
gene	NULL
enhancer	NULL
activity	NULL
by	NULL
the	NULL
T-cell	NULL
accessory	NULL
molecule	NULL
CD28	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

251:313-316	NULL
.	NULL

1488	NULL
9	NULL
.	NULL

Williams	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
D.	NULL
Moolten	NULL
,	NULL
J.	NULL
Burlein	NULL
,	NULL
J.	NULL
Romano	NULL
,	NULL
R.	NULL
Bhaerman	NULL
,	NULL
A.	NULL
Godillot	NULL
,	NULL
M.	NULL
Mellon	NULL
,	NULL
F.	NULL
J.	NULL
Rauscher	NULL
IH	NULL
,	NULL
and	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
.	NULL

1991	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
zinc	NULL
finger	NULL
protein	NULL
that	NULL
inhibits	NULL
IL-2	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

254:1791-1793	NULL
.	NULL

10	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
M.	NULL
P.	NULL
Felli	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
A.	NULL
Gismondi	NULL
,	NULL
A.	NULL
Santoni	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
regulation	NULL
of	NULL
the	NULL
interleukin-2	NULL
gene	NULL
by	NULL
glucocorticoid	NULL
hormones	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265:8075-8080	NULL
.	NULL

11	NULL
.	NULL

Vacca	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
P.	NULL
Felli	NULL
,	NULL
A.	NULL
R.	NULL
Farina	NULL
,	NULL
S.	NULL
Martinotti	NULL
,	NULL
M.	NULL
Maroder	NULL
,	NULL
I.	NULL
Screpanti	NULL
,	NULL
D.	NULL
Meco	NULL
,	NULL
E.	NULL
Petrangeli	NULL
,	NULL
L.	NULL
Frati	NULL
,	NULL
and	NULL
A.	NULL
Gulino	NULL
.	NULL

1992	NULL
.	NULL

Glucocorticoid	NULL
receptor-mediated	NULL
suppression	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
expression	NULL
through	NULL
impairment	NULL
of	NULL
the	NULL
cooperativity	NULL
between	NULL
nuclear	NULL
factor	NULL
at	NULL
activated	NULL
T	NULL
celis	NULL
and	NULL
AP-1	NULL
enhancer	NULL
elements	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:637-646	NULL
.	NULL

12	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
P.	NULL
S.	NULL
Mattila	NULL
.	NULL

1992	NULL
.	NULL

Negative	NULL
regulation	NULL
of	NULL
interleukin	NULL
2	NULL
transcription	NULL
by	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

175:1235-1245	NULL
.	NULL

13	NULL
.	NULL

Kronke	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
W.	NULL
J.	NULL
Leonard	NULL
,	NULL
J.	NULL
M.	NULL
Depper	NULL
,	NULL
S.	NULL
K.	NULL
Arya	NULL
,	NULL
F.	NULL
Wong-Staal	NULL
,	NULL
R.	NULL
C.	NULL
Gallo	NULL
,	NULL
T.	NULL
A.	NULL
Waldmann	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1984	NULL
.	NULL

Cyclosporine	NULL
inhibits	NULL
T-cell	NULL
growth	NULL
factor	NULL
gene	NULL
expression	NULL
at	NULL
the	NULL
level	NULL
of	NULL
mRNA	NULL
transcription	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

§	NULL
$	NULL
1:5214-5218	NULL
.	NULL

14	NULL
.	NULL

Emmel	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
K.	NULL
M.	NULL
Higgins	NULL
,	NULL
E.	NULL
Lacy	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1989	NULL
.	NULL

Cyclosporin	NULL
A	NULL
specifically	NULL
inhibits	NULL
function	NULL
of	NULL
nuclear	NULL
proteins	NULL
involved	NULL
in	NULL
T	NULL
cell	NULL
activation	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

246:1617-1619	NULL
.	NULL

15	NULL
.	NULL

Mattila	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
K.	NULL
S.	NULL
Ullman	NULL
,	NULL
S.	NULL
Fiering	NULL
,	NULL
E.	NULL
A.	NULL
Emmuel	NULL
,	NULL
M.	NULL
McCutcheon	NULL
,	NULL
G.	NULL
R.	NULL
Crabtree	NULL
,	NULL
and	NULL
L.	NULL
Herzenberg	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK	NULL
506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

9:4425-4433	NULL
.	NULL

16	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
P.	NULL
Nolan	NULL
,	NULL
K.	NULL
Inaba	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Steinman	NULL
.	NULL

1990	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
immunosuppressive	NULL
agents	NULL
on	NULL
the	NULL
induction	NULL
of	NULL
nuclear	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
sites	NULL
on	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

172:1869-1872	NULL
.	NULL

17	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
L.	NULL
Hennighausay	NULL
,	NULL
and	NULL
U.	NULL
Siebenlist	NULL
.	NULL

1990	NULL
.	NULL

Inducible	NULL
nuclear	NULL
factor	NULL
binding	NULL
to	NULL
the	NULL
kB	NULL
elements	NULL
of	NULL
the	NULL
human	NULL
immunodeficiency	NULL
virus	NULL
enhancer	NULL
in	NULL
T	NULL
cells	NULL
can	NULL
be	NULL
blocked	NULL
by	NULL
cyclosporin	NULL
A	NULL
in	NULL
a	NULL
signal-dependent	NULL
manner	NULL
.	NULL

J.	NULL
Virol	NULL
.	NULL

64:4037-4041	NULL
.	NULL

18	NULL
.	NULL

Dignam	NULL
,	NULL
J.	NULL
D.	NULL
,	NULL
R.	NULL
M.	NULL
Lebovitz	NULL
,	NULL
and	NULL
R.	NULL
G.	NULL
Roeder	NULL
.	NULL

1983	NULL
.	NULL

Accurate	NULL
transcription	NULL
initiation	NULL
by	NULL
RNA	NULL
polymerase	NULL
II	NULL
in	NULL
a	NULL
soluble	NULL
extract	NULL
from	NULL
isolated	NULL
mammalian	NULL
nuclei	NULL
.	NULL

Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

11:1475-1489	NULL
.	NULL

19	NULL
.	NULL

Bradford	NULL
,	NULL
M.	NULL
1976	NULL
.	NULL

A	NULL
rapid	NULL
and	NULL
sensitive	NULL
method	NULL
for	NULL
the	NULL
quantitation	NULL
of	NULL
microgram	NULL
quantities	NULL
of	NULL
protein	NULL
utilizing	NULL
the	NULL
principle	NULL
of	NULL
protein	NULL
dye	NULL
dingins	NULL
.	NULL

Anal	NULL
.	NULL

Biochem	NULL
.	NULL

72:248-254	NULL
.	NULL

20	NULL
.	NULL

Kovary	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
R.	NULL
Bravo	NULL
.	NULL

1991	NULL
.	NULL

Expression	NULL
of	NULL
different	NULL
jun	NULL
and	NULL
fos	NULL
proteins	NULL
during	NULL
the	NULL
GO-to-G	NULL
1	NULL
transition	NULL
in	NULL
mouse	NULL
fibroblasts	NULL
:	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
association	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

5:2451-2459	NULL
.	NULL

21	NULL
.	NULL

Granelli-Piperno	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
P.	NULL
Nolan	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
transcription	NULL
factors	NULL
that	NULL
bind	NULL
to	NULL
elements	NULL
of	NULL
the	NULL
IL-2	NULL
promoter	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:2734-2739	NULL
.	NULL

22	NULL
.	NULL

Siebenlist	NULL
,	NULL
U.	NULL
,	NULL
D.	NULL
B.	NULL
Durand	NULL
,	NULL
P.	NULL
Bressler	NULL
,	NULL
N.	NULL
J.	NULL
Holbrook	NULL
,	NULL
C.	NULL
A.	NULL
Norris	NULL
,	NULL
M.	NULL
Camoun	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Kant	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1986	NULL
.	NULL

Promoter	NULL
region	NULL
of	NULL
interieukin-2	NULL
gene	NULL
undergoes	NULL
chromatin	NULL
structure	NULL
changes	NULL
and	NULL
confers	NULL
inducibility	NULL
on	NULL
chloramphenicol	NULL
acetyitransferase	NULL
gene	NULL
during	NULL
activation	NULL
of	NULL
T	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

6:3042-3049	NULL
.	NULL

23	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
E.	NULL
A.	NULL
Allegretto	NULL
,	NULL
S.	NULL
O.	NULL
Kino	NULL
,	NULL
K.	NULL
Hatton	NULL
,	NULL
W.	NULL
Boyle	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
jun	NULL
oncogene	NULL
encodes	NULL
a	NULL
sequence-specific	NULL
trans-activator	NULL
similar	NULL
to	NULL
AP-1	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

332:166-171	NULL
.	NULL

24	NULL
.	NULL

Bours	NULL
,	NULL
V.	NULL
,	NULL
P.	NULL
R.	NULL
Burd	NULL
,	NULL
K.	NULL
Brown	NULL
,	NULL
J.	NULL
Villalobos	NULL
,	NULL
S.	NULL
Park	NULL
,	NULL
R-P.	NULL
Ryseck	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
K.	NULL
Kelly	NULL
,	NULL
and	NULL
U.	NULL
Sicbenlist	NULL
.	NULL

1992	NULL
.	NULL

A	NULL
novel	NULL
mitogen-inducible	NULL
gene	NULL
product	NULL
related	NULL
to	NULL
p50	NULL
/p105-NFkB	NULL
participated	NULL
in	NULL
transactivation	NULL
through	NULL
a	NULL
kB	NULL
site	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

12:685-695	NULL
.	NULL

25	NULL
.	NULL

Gorman	NULL
,	NULL
C.	NULL
M.	NULL
,	NULL
L.	NULL
F.	NULL
Moftat	NULL
,	NULL
and	NULL
B.	NULL
H.	NULL
Howard	NULL
.	NULL

1982	NULL
.	NULL

Recombinant	NULL
genomes	NULL
which	NULL
express	NULL
chloramphenicol	NULL
acetyltransferase	NULL
in	NULL
mammalian	NULL
cells	NULL
.	NULL

Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

2:1044-1051	NULL
.	NULL

26	NULL
.	NULL

Hoyos	NULL
,	NULL
B.	NULL
,	NULL
D.	NULL
W.	NULL
Ballard	NULL
,	NULL
E.	NULL
Bohnlein	NULL
,	NULL
M.	NULL
Sickevits	NULL
,	NULL
and	NULL
W.	NULL
C.	NULL
Greene	NULL
.	NULL

1989	NULL
.	NULL

Kappa	NULL
B-specific	NULL
DNA	NULL
binding	NULL
proteins	NULL
:	NULL
role	NULL
in	NULL
the	NULL
regulation	NULL
of	NULL
human	NULL
interleukin-2	NULL
gene	NULL
expression	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

244:457-460	NULL
.	NULL

27	NULL
.	NULL

Ullman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
J.	NULL
P.	NULL
Northrop	NULL
,	NULL
C.	NULL
L.	NULL
Verweij	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1990	NULL
.	NULL

Transmission	NULL
of	NULL
signals	NULL
from	NULL
the	NULL
T	NULL
lymphocyte	NULL
antigen	NULL
receptor	NULL
to	NULL
the	NULL
genes	NULL
responsible	NULL
for	NULL
cell	NULL
proliferation	NULL
and	NULL
immune	NULL
function	NULL
:	NULL
the	NULL
missing	NULL
link	NULL
.	NULL

Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

$	NULL
:421-452	NULL
.	NULL

28	NULL
.	NULL

Jonat	NULL
,	NULL
C.	NULL
,	NULL
H.	NULL
J.	NULL
Rahmsdorf	NULL
,	NULL
K.	NULL
K.	NULL
Park	NULL
,	NULL
A.	NULL
C.	NULL
B.	NULL
Cato	NULL
,	NULL
S.	NULL
Gebel	NULL
,	NULL
H.	NULL
Ponta	NULL
,	NULL
and	NULL
P.	NULL
Herrlich	NULL
.	NULL

1990	NULL
.	NULL

Antitumor	NULL
promotion	NULL
and	NULL
antiinflammation	NULL
:	NULL
down-modulation	NULL
of	NULL
AP-	NULL
!	NULL

(	NULL
Fos/Jun	NULL
)	NULL
activity	NULL
by	NULL
glucocorticoid	NULL
hormone	NULL
.	NULL

CelZ	NULL
.	NULL

62:1189-1204	NULL
.	NULL

29	NULL
.	NULL

Yang-Yen	NULL
,	NULL
H.	NULL
J.	NULL
,	NULL
J.	NULL
C.	NULL
Chambard	NULL
,	NULL
Y.	NULL
L.	NULL
Sun	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
J.	NULL
Schmidt	NULL
,	NULL
J.	NULL
Drouin	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1990	NULL
.	NULL

Transcriptional	NULL
interference	NULL
between	NULL
c-jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
:	NULL
mutual	NULL
inhibition	NULL
of	NULL
DNA	NULL
binding	NULL
due	NULL
to	NULL
direct	NULL
protein-protein	NULL
interaction	NULL
.	NULL

Cel/	NULL
.	NULL

62:1205-1215	NULL
.	NULL

30	NULL
.	NULL

Schule	NULL
,	NULL
R.	NULL
,	NULL
P.	NULL
Ranganajan	NULL
,	NULL
S.	NULL
Kliewev	NULL
,	NULL
L.	NULL
J.	NULL
Ransome	NULL
,	NULL
J.	NULL
Bolado	NULL
,	NULL
N.	NULL
Yang	NULL
,	NULL
I.	NULL
M.	NULL
Verna	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1990	NULL
.	NULL

Functional	NULL
antagonism	NULL
between	NULL
oncopro-tein	NULL
c-jun	NULL
and	NULL
the	NULL
glucocorticoid	NULL
receptor	NULL
.	NULL

Cell	NULL
.	NULL

62:1217-1226	NULL
.	NULL

F.	NULL
Paliogianni	NULL
,	NULL
A.	NULL
Raptis	NULL
,	NULL
S.	NULL
S.	NULL
Ahuja	NULL
,	NULL
S.	NULL
M.	NULL
Najjar	NULL
,	NULL
and	NULL
D.	NULL
T.	NULL
Boumpas	NULL
31	NULL
,	NULL
Lee	NULL
,	NULL
W.	NULL
,	NULL
A.	NULL
Haslinger	NULL
,	NULL
M.	NULL
Karin	NULL
,	NULL
and	NULL
R.	NULL
Tijan	NULL
.	NULL

1987	NULL
.	NULL

Activation	NULL
of	NULL
transcription	NULL
by	NULL
two	NULL
factors	NULL
that	NULL
bind	NULL
promoter	NULL
and	NULL
enhancer	NULL
sequences	NULL
of	NULL
the	NULL
human	NULL
metallothionein	NULL
gene	NULL
and	NULL
SV40	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

325:368-372	NULL
.	NULL

32	NULL
.	NULL

Angel	NULL
,	NULL
P.	NULL
,	NULL
E.	NULL
A.	NULL
Allegretto	NULL
,	NULL
S.	NULL
T.	NULL
Okino	NULL
,	NULL
K.	NULL
Hattori	NULL
,	NULL
W.	NULL
J.	NULL
Boyle	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

Oncogene	NULL
jun	NULL
encodes	NULL
a	NULL
sequence-specific	NULL
trans-activator	NULL
similar	NULL
to	NULL
AP-1	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

332:166-171	NULL
.	NULL

33	NULL
.	NULL

Hirai	NULL
,	NULL
S.	NULL
I.	NULL
,	NULL
R.	NULL
P.	NULL
Rysech	NULL
,	NULL
F.	NULL
Mechta	NULL
,	NULL
R.	NULL
Bravo	NULL
,	NULL
and	NULL
M.	NULL
Yaniv	NULL
.	NULL

1989	NULL
.	NULL

Characterization	NULL
of	NULL
jun	NULL
:	NULL
a	NULL
new	NULL
member	NULL
of	NULL
the	NULL
jun	NULL
proto-oncogene	NULL
family	NULL
.	NULL

EMBO	NULL
(	NULL
Eur	NULL
.	NULL

Mol	NULL
.	NULL

Biol	NULL
.	NULL

Organ	NULL
.	NULL
)	NULL

J	NULL
.	NULL

8:1433-1439	NULL
.	NULL

34	NULL
.	NULL

Chiu	NULL
,	NULL
R.	NULL
,	NULL
W.	NULL
J.	NULL
Boyle	NULL
,	NULL
J.	NULL
Meeks	NULL
,	NULL
T.	NULL
Smeal	NULL
,	NULL
T.	NULL
Hunter	NULL
,	NULL
and	NULL
M.	NULL
Karin	NULL
.	NULL

1988	NULL
.	NULL

The	NULL
c-fos	NULL
protein	NULL
interacts	NULL
with	NULL
c-jun/AP-1	NULL
to	NULL
stimulate	NULL
transcription	NULL
of	NULL
AP-1	NULL
responsive	NULL
genes	NULL
.	NULL

Cell	NULL
.	NULL

54:541-552	NULL
.	NULL

35	NULL
.	NULL

Flanagan	NULL
,	NULL
W.	NULL
M.	NULL
,	NULL
B.	NULL
Corthésy	NULL
,	NULL
R.	NULL
J.	NULL
Bram	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

Nuclear	NULL
association	NULL
of	NULL
a	NULL
T-cell	NULL
transcription	NULL
factor	NULL
blocked	NULL
by	NULL
FK-506	NULL
and	NULL
cyclosporin	NULL
A	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

352:803-806	NULL
.	NULL

36	NULL
.	NULL

Jain	NULL
,	NULL
J.	NULL
,	NULL
P.	NULL
G.	NULL
McCaffrey	NULL
,	NULL
V.	NULL
E.	NULL
Valge-Archer	NULL
,	NULL
and	NULL
A.	NULL
Rao	NULL
.	NULL

1992	NULL
.	NULL

Nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
contain	NULL
Fos	NULL
and	NULL
Jun	NULL
.	NULL

Nature	NULL
(	NULL
Lond	NULL
.	NULL
)	NULL

.	NULL

356:801-804	NULL
.	NULL

37	NULL
.	NULL

Uliman	NULL
,	NULL
K.	NULL
S.	NULL
,	NULL
W.	NULL
M.	NULL
Flanagan	NULL
,	NULL
C.	NULL
A.	NULL
Edwards	NULL
,	NULL
and	NULL
G.	NULL
R.	NULL
Crabtree	NULL
.	NULL

1991	NULL
.	NULL

An	NULL
inducible	NULL
protein	NULL
,	NULL
OAP	NULL
,	NULL
interacts	NULL
with	NULL
OCT-1	NULL
to	NULL
transcriptionally	NULL
activate	NULL
early	NULL
genes	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

254:558-561	NULL
.	NULL

38	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
J.	NULL
W.	NULL
Pierce	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1987	NULL
.	NULL

Protein-binding	NULL
motifs	NULL
in	NULL
immunoglobulin	NULL
enhancers	NULL
determine	NULL
transcriptional	NULL
activity	NULL
and	NULL
in-ducibility	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

236:1573-1577	NULL
.	NULL

39	NULL
.	NULL

Wall	NULL
,	NULL
R.	NULL
,	NULL
M.	NULL
Briskin	NULL
,	NULL
C.	NULL
Carter	NULL
,	NULL
H.	NULL
Govan	NULL
,	NULL
A.	NULL
Taylor	NULL
,	NULL
and	NULL
P.	NULL
Kincade	NULL
.	NULL

1988	NULL
.	NULL

A	NULL
labile	NULL
inhibitor	NULL
blocks	NULL
immunoglobulin	NULL
k-light-chain-gene	NULL
transcription	NULL
in	NULL
a	NULL
pre-B	NULL
leukemic	NULL
cell	NULL
.	NULL

Proc	NULL
.	NULL

Nat	NULL
!	NULL

.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

$	NULL
3:295-298	NULL
.	NULL

40	NULL
.	NULL

Lenardo	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
A.	NULL
Kuang	NULL
,	NULL
A.	NULL
Gifford	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

NF-kB	NULL
protein	NULL
purification	NULL
from	NULL
bovine	NULL
spleen	NULL
:	NULL
nucleotide	NULL
stimulation	NULL
and	NULL
binding	NULL
site	NULL
specificity	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
.	NULL

85:8825-8829	NULL
.	NULL

41	NULL
.	NULL

Baeuerle	NULL
,	NULL
P.	NULL
A.	NULL
,	NULL
and	NULL
D.	NULL
Baltimore	NULL
.	NULL

1988	NULL
.	NULL

I-Kappa	NULL
B	NULL
:	NULL
a	NULL
specific	NULL
inhibitor	NULL
of	NULL
the	NULL
NF-Kappa	NULL
B	NULL
transcription	NULL
factor	NULL
.	NULL

Science	NULL
(	NULL
Wash.	NULL
DC	NULL
)	NULL
.	NULL

242:540-546	NULL
.	NULL

42	NULL
.	NULL

Claman	NULL
,	NULL
H.	NULL
J	NULL
.	NULL

1972	NULL
.	NULL

Corticosteroids	NULL
and	NULL
lymphoid	NULL
cells	NULL
.	NULL

N.	NULL
Eng	NULL
!	NULL

.	NULL

J.	NULL
Med	NULL
.	NULL

287:388-397	NULL
.	NULL

Mechanism	NULL
of	NULL
Immunosuppression	NULL
by	NULL
Glucocorticoids	NULL
__	NULL
1489	NULL

